Influenza, Influenza Vaccines
Conditions
Keywords
Pandemic Flu, Pandemic influenza vaccine (GSK1119711A)
Brief summary
The aim of the study is to assess the safety & immunogenicity of a pandemic influenza vaccine administered at 2 different time points. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Interventions
BIOLOGICALPandemic influenza vaccine (GSK1119711A)-formulation 1
2 or 3 doses, intramuscular injection, at different time points.
BIOLOGICALPandemic influenza vaccine (GSK1119711A)-formulation 2
2 or 3 doses, intramuscular injection, at different time points.
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study. * A male or female between, and including, 18 and 60 years of age at the time of the first vaccination. * Written informed consent obtained from the subject. * Healthy subjects as established by medical history and clinical examination before entering into the study. * If the subject is female, she must be of non-childbearing potential; or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to first vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after completion of the vaccination series.
Exclusion criteria
* Administration of licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study. * History of vaccination with investigational influenza pandemic vaccine. * History of administration of an experimental/licensed vaccine * Planned administration of a vaccine not foreseen by the study protocol during the following periods: from Day 0 up to Day 51; from 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to Month 6 and Month 12; from Month 6 up to Month 6 + 30 days; from Month 12 up to Month 12 + 30 days. * Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first administration of the candidate vaccines * Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination * History of hypersensitivity to vaccines. * History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. * History of chronic alcohol consumption and/or drug abuse. * Acute clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests. * Serious chronic disease including any medically significant chronic pulmonary, cardiovascular, renal, neurological, psychiatric or metabolic disorder, as determined by medical history and physical examination. * Acute disease at the time of enrolment. * Administration of immunoglobulins and/or any blood products within the three months preceding the first administration of the candidate vaccine or during the study. * Lactating women. * Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days prior to the first vaccination, or planned use during the study period. * Any condition which, in the opinion of the investigator, prevents the subject from participation in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value | At Day 0 | The seropositivity cut-off for the assay was an antibody titer equal to or above (≥) 1:10, in the sera of subjects seronegative before vaccination. The flu strains assessed were A/Indonesia/05/2005 and A/Vietnam/1194/2004, for adults who received the booster dose at Month 6. |
| Geometric Mean Titers (GMTs) of H5N1 HI Antibodies | At Day 0 | GMTs were calculated for H5N1 HI antibodies against the A/Vietnam/1194/2004 or A/Indonesia/05/2005 strains, for the groups who received the booster dose at Month 6. |
| Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | At Month 6 | The seroconversion factor (SCF) was defined as the fold change in serum H5N1 HI geometric mean titers (GMTs) post-vaccination compared to Day 0. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/5/2005, for adults who received the booster dose at Month 6. |
| Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | At Month 6 | A seroconverted (SCR) subject was defined as a vaccinated subject who had either a pre-vaccination titer \< 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and at least a four-fold increase in post-vaccination titer. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/5/2005, for adults who received the booster dose at Month 6. |
| Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | At Day 0 | A seroprotected (SPR) subject was defined as a vaccinated subject with serum H5N1 HI titer ≥ 1:40. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/5/2005, for adults who received the booster dose at Month 6. |
| Number of Subjects With Any and Grade 3 Solicited Local Symptoms | During the 7-day (Days 0-6) post-vaccination period following each dose and across doses, up to 6/12 months + 7 days | Assessed solicited local symptoms were ecchymosis, induration, pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 ecchymosis/induration/redness/swelling = spreading beyond 100 millimeters (mm) of injection site. |
| Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | During the 7-day (Days 0-6) post-vaccination period following each dose and across doses, up to 12 months + 7 days | Assessed solicited general symptoms were arthralgia, fatigue, fever \[defined as axillary temperature above (\>) 38 degrees Celsius (°C)\], headache, myalgia, shivering and sweating. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 40.0 °C. Related = symptom assessed by the investigator as related to the vaccination. |
| Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | During the 30-day (Days 0-29) post-primary vaccination period (Month 6 + 30 days) | An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination. |
| Number of Subjects With Serious Adverse Events (SAEs) | During the entire study period (Day 0 to Month 18) | Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. |
| Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease | At Month 6 + 7 Days | Booster seroconversion (SCR) was defined as: For seronegative subjects at pre-booster (Month 6), antibody titer ≥ 1:40 at Month 6 + 7 days; For seropositive subjects at pre-booster (Month 6), antibody titer at Month 6 + 7 days ≥ 4 fold the pre-vaccination antibody titer at Month 6. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/5/2005, for adults who received the booster dose at Month 6. |
| Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease | At Month 6 + 7 Days | Booster Factor (Seroconversion Factor booster) was defined as the fold change in H5N1 HI antibodies between the pre- and post-booster vaccination time-points (mean\[log10(POST/M6)\]). The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/05/2005, for groups who received the booster dose at Month 6. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | At Day 0, Month 6, Month 12, Month 12 + 7 Days, Month 12 + 21 Days and Month 18 | Among cytokines expressed after background reduction were cluster of differentiation 4 all doubles (CD4 All Doubles), cluster of differentiation 40-ligand (CD40-L), interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α). The 2 flu strains assessed were A/Indonesia/05/2005 and A/Vietnam/1194/2004. |
| GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | At Day 0, Day 21, Day 42, Month 6, Month 6 + 7 Days, Month 6 + 21 Days and Month 12 | GMTs were calculated for H5N1 neutralizing antibodies against the A/Vietnam/1194/2004 or A/Indonesia/05/2005 strains. |
| GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | At Day 0, Day 21, Day 42, Month 6, Month 12, Month 12 + 7 Days and Month 12 + 21 Days | GMTs were calculated for H5N1 neutralizing antibodies against the A/Vietnam/1194/2004 or A/Indonesia/05/2005 strains. |
| GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | At Day 0, Day 21, Day 42, Month 6, Month 6 + 7 Days, Month 6 + 21 Days, Month 12 and Month 18 | GMTs were calculated for H5N1 neutralizing antibodies against the A/Vietnam/1194/2004 or A/Indonesia/05/2005 strains. |
| GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | At Day 0, Day 21, Day 42, Month 6, Month 12, Month 12 + 7 Days, Month 12 + 21 Days and at Month 18 | GMTs were calculated for H5N1 HI antibodies against the A/Vietnam/1194/2004 or A/Indonesia/05/2005 strains. |
| Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | At Day 21, Day 42, Month 6, Month 6 + 7 Days, Month 6 + 21 Days and Month 12 | Seroconversion (SCR) was defined as the percentage of vaccinees with a minimum 4-fold increase in neutralizing antibody titer at the post-vaccination time-point compared to Day 0. The 2 flu strains assessed were A/Vietnam/1194/2004 (H5N1) and A/Indonesia/5/2005 (H5N1). |
| Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | At Day 21, Day 42, Month 6, Month 12, Month 12 + 7 Days and Month 12 + 21 Days | Seroconversion (SCR) was defined as the percentage of vaccinees with a minimum 4-fold increase in neutralizing antibody titer at the post-vaccination time-point compared to Day 0. The 2 flu strains assessed were A/Vietnam/1194/2004 (H5N1) and A/Indonesia/5/2005 (H5N1). |
| Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | At Month 6 + 7 Days, Month 6 + 21 Days, Month 12 and Month 18 | Booster SCR was defined as: For seronegative subjects at pre-booster (Month 6), antibody titer ≥ 1:40 at Month 6 + 7 days; For seropositive subjects at pre-booster (Month 6), antibody titer at Month 6 + 7 days ≥ 4 fold the pre-vaccination antibody titer at Month 6. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/5/2005. |
| Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | At Month 12 + 7 Days and Month 12 + 21 Days | Booster seroconversion (SCR) was defined as: For seronegative subjects at pre-booster (Month 12), antibody titer ≥ 1:40 at Month 12 + 7 days; For seropositive subjects at pre-booster (Month 12), antibody titer at Month 12 + 7 days ≥ 4 fold the pre-vaccination antibody titer at Month 12. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/5/2005. |
| GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | At Day 0, Day 21, Day 42, Month 6, Month 12, Month 12 + 7 Days, Month 12 + 21 Days and Month 18 | GMTs were calculated for H5N1 neutralizing antibodies against the A/Vietnam/1194/2004 or A/Indonesia/05/2005 strains. |
| Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | At Day 21, Day 42, Month 6, Month 12, Month 12 + 7 Days, Month 12 + 21 Days | A seroconverted (SCR) subject was defined as a vaccinated subject who had either a pre-vaccination titer \< 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and at least a four-fold increase in post-vaccination titer. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/5/2005. |
| Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | At Day 21, Day 42, Month 6, Month 12, Month 12 + 7 Days, Month 12 + 21 Days | The seroconversion factor (SCF) was defined as the fold change in serum hemagglutination inhibition (HI) geometric mean titers (GMTs) post-vaccination compared to Day 0. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/5/2005. |
| Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | At Day 0, Day 21, Day 42, Month 6, Month 12, Month 12 + 7 Days, Month 12 + 21 Days | A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40. The 2 flu strains assessed were A/Vietnam/1194/2004 (H5N1) and A/Indonesia/5/2005 (H5N1). |
| GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | At Day 0, Day 21, Day 42, Month 6, Month 6+ 7 Days, Month 6+ 21 Days, Month 12 and at Month 18 | GMTs were calculated for H5N1 HI antibodies against the A/Vietnam/1194/2004 or A/Indonesia/05/2005 strains. |
| Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | At Day 21, Day 42, Month 6, Month 6 + 7 Days, Month 6 + 21 Days, Month 12 and Month 18 | A seroconverted (SCR) subject was defined as a vaccinated subject who had either a pre-vaccination titer \<1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 2 flu strains assessed were A/Vietnam/1194/2004 (H5N1) and A/Indonesia/5/2005 (H5N1). |
| Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | At Day 21, Day 42, Month 6, Month 6 + 7 Days, Month 6 + 21 Days, Month 12 and Month 18 | The seroconversion factor (SCF) was defined as the fold change in serum hemagglutination inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0. The 2 flu strains assessed were A/Vietnam/1194/2004 (H5N1) and A/Indonesia/5/2005 (H5N1). |
| Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | At Day 0, Day 21, Day 42, Month 6, Month 6+ 7 Days, Month 6+ 21 Days, Month 12 and Month 18 | A seroprotected (SPR) subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40. The 2 flu strains assessed were A/Vietnam/1194/2004 (H5N1) and A/Indonesia/5/2005 (H5N1). |
| Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, A/Vietnam/1194/2004 and A/Indonesia/5/2005, for Groups Who Received Booster Dose at Month 12 | At Month 12 + 7 Days, Month 12 + 21 Days and Month 18 | Booster seroconversion (SCR) was defined as: For seronegative subjects at pre-booster (Month 12), antibody titer ≥ 1:40 at Month 12 + 7 days; For seropositive subjects at pre-booster (Month 12), antibody titer at Month 12 + 7 days ≥ 4 fold the pre-vaccination antibody titer at Month 12. |
| Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | At Month 12 + 7 Days and at Month 12 + 21 Days | Booster Factor (Seroconversion Factor booster) was defined as the fold change in H5N1 HI antibodies between the pre- and post-booster vaccination time-points (mean\[log10(POST/M12)\]). The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/05/2005, for groups who received the booster dose at Month 12. |
| Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | At Day 0, Month 6, Month 6 + 7 Days, Month 6 + 21 Days, Month 12 and Month 18 | Among cytokines expressed after background reduction were cluster of differentiation 4 all doubles (CD4 All Doubles), cluster of differentiation 40-ligand (CD40-L), interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α). The 2 flu strains assessed were A/Indonesia/05/2005 and A/Vietnam/1194/2004. |
Countries
Germany
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| GSK1562902A V/I/6 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm. | 63 |
| GSK1562902A V/V/6 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm. | 66 |
| GSK1562902A 2V/I/6 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6.The vaccine was administered in the deltoid region of the non-dominant arm. | 64 |
| GSK1562902A 2V/V/6 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm. | 63 |
| GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm. | 64 |
| GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm. | 64 |
| GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12.The vaccine was administered in the deltoid region of the non-dominant arm. | 65 |
| GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm. | 63 |
| Total | 512 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 |
|---|---|---|---|---|---|---|---|---|---|
| Overall Study | Adverse Event | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 |
| Overall Study | Lost to Follow-up | 7 | 8 | 3 | 5 | 5 | 2 | 8 | 10 |
| Overall Study | Pregnancy | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Overall Study | Protocol Violation | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Overall Study | Vaccine Expired | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Overall Study | Withdrawal by Subject | 3 | 1 | 0 | 3 | 0 | 0 | 0 | 2 |
Baseline characteristics
| Characteristic | GSK1562902A V/I/6 Group | GSK1562902A V/V/6 Group | GSK1562902A 2V/I/6 Group | GSK1562902A 2V/V/6 Group | GSK1562902A V/I/12 Group | GSK1562902A V/V/12 Group | GSK1562902A 2V/I/12 Group | GSK1562902A 2V/V/12 Group | Total |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 34.6 Years STANDARD_DEVIATION 12.9 | 33.1 Years STANDARD_DEVIATION 11.4 | 33.8 Years STANDARD_DEVIATION 11.8 | 33.4 Years STANDARD_DEVIATION 12.4 | 34.6 Years STANDARD_DEVIATION 12.9 | 34.8 Years STANDARD_DEVIATION 12.9 | 33.2 Years STANDARD_DEVIATION 11.2 | 34.3 Years STANDARD_DEVIATION 11.6 | 34.0 Years STANDARD_DEVIATION 12.1 |
| Race/Ethnicity, Customized Caucasian / European heritage | 63 Participants | 64 Participants | 62 Participants | 61 Participants | 64 Participants | 61 Participants | 63 Participants | 62 Participants | 500 Participants |
| Race/Ethnicity, Customized Others | 0 Participants | 2 Participants | 2 Participants | 2 Participants | 0 Participants | 3 Participants | 2 Participants | 1 Participants | 12 Participants |
| Sex: Female, Male Female | 32 Participants | 35 Participants | 33 Participants | 37 Participants | 37 Participants | 27 Participants | 36 Participants | 36 Participants | 273 Participants |
| Sex: Female, Male Male | 31 Participants | 31 Participants | 31 Participants | 26 Participants | 27 Participants | 37 Participants | 29 Participants | 27 Participants | 239 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk |
|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 63 | 0 / 66 | 0 / 64 | 0 / 63 | 0 / 64 | 1 / 64 | 0 / 65 | 0 / 63 |
| other Total, other adverse events | 58 / 63 | 65 / 66 | 63 / 64 | 61 / 63 | 61 / 64 | 60 / 64 | 65 / 65 | 62 / 63 |
| serious Total, serious adverse events | 4 / 63 | 1 / 66 | 0 / 64 | 3 / 63 | 1 / 64 | 5 / 64 | 1 / 65 | 3 / 63 |
Outcome results
Primary
Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease
Booster Factor (Seroconversion Factor booster) was defined as the fold change in H5N1 HI antibodies between the pre- and post-booster vaccination time-points (mean\[log10(POST/M6)\]). The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/05/2005, for groups who received the booster dose at Month 6.
Time frame: At Month 6 + 7 Days
Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 7 Days | 27.9 Fold Increase |
| GSK1562902A V/I/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 7 Days | 18.2 Fold Increase |
| GSK1562902A V/V/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 7 Days | 20.3 Fold Increase |
| GSK1562902A V/V/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 7 Days | 12.3 Fold Increase |
| GSK1562902A 2V/I/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 7 Days | 6.3 Fold Increase |
| GSK1562902A 2V/I/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 7 Days | 14.5 Fold Increase |
| GSK1562902A 2V/V/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 7 Days | 6.9 Fold Increase |
| GSK1562902A 2V/V/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 7 Days | 9.2 Fold Increase |
Primary
Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease
Booster Factor (Seroconversion Factor booster) was defined as the fold change in H5N1 HI antibodies between the pre- and post-booster vaccination time-points (mean\[log10(POST/M6)\]). The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/05/2005, for groups who received the booster dose at Month 6.
Time frame: At Month 6 + 21 Days
Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 21 Days | 55.3 Fold Increase |
| GSK1562902A V/I/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 21 Days | 35.4 Fold Increase |
| GSK1562902A V/V/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 21 Days | 29.2 Fold Increase |
| GSK1562902A V/V/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 21 Days | 17.6 Fold Increase |
| GSK1562902A 2V/I/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 21 Days | 45.6 Fold Increase |
| GSK1562902A 2V/I/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 21 Days | 19.1 Fold Increase |
| GSK1562902A 2V/V/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 21 Days | 17.9 Fold Increase |
| GSK1562902A 2V/V/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 21 Days | 11.5 Fold Increase |
Primary
Geometric Mean Titers (GMTs) of H5N1 HI Antibodies
GMTs were calculated for H5N1 HI antibodies against the A/Vietnam/1194/2004 or A/Indonesia/05/2005 strains, for the groups who received the booster dose at Month 6.
Time frame: At Month 6
Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Geometric Mean Titers (GMTs) of H5N1 HI Antibodies | A/Indonesia, Month 6 | 5.5 Titers |
| GSK1562902A V/I/6 Group | Geometric Mean Titers (GMTs) of H5N1 HI Antibodies | A/Vietnam, Month 6 | 12.0 Titers |
| GSK1562902A V/V/6 Group | Geometric Mean Titers (GMTs) of H5N1 HI Antibodies | A/Vietnam, Month 6 | 9.7 Titers |
| GSK1562902A V/V/6 Group | Geometric Mean Titers (GMTs) of H5N1 HI Antibodies | A/Indonesia, Month 6 | 5.3 Titers |
| GSK1562902A 2V/I/6 Group | Geometric Mean Titers (GMTs) of H5N1 HI Antibodies | A/Indonesia, Month 6 | 8.6 Titers |
| GSK1562902A 2V/I/6 Group | Geometric Mean Titers (GMTs) of H5N1 HI Antibodies | A/Vietnam, Month 6 | 29.9 Titers |
| GSK1562902A 2V/V/6 Group | Geometric Mean Titers (GMTs) of H5N1 HI Antibodies | A/Indonesia, Month 6 | 7.2 Titers |
| GSK1562902A 2V/V/6 Group | Geometric Mean Titers (GMTs) of H5N1 HI Antibodies | A/Vietnam, Month 6 | 32.0 Titers |
Primary
Geometric Mean Titers (GMTs) of H5N1 HI Antibodies
GMTs were calculated for H5N1 HI antibodies against the A/Vietnam/1194/2004 or A/Indonesia/05/2005 strains, for the groups who received the booster dose at Month 6.
Time frame: At Day 0
Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Geometric Mean Titers (GMTs) of H5N1 HI Antibodies | A/Indonesia, Day 0 | 5.0 Titers |
| GSK1562902A V/I/6 Group | Geometric Mean Titers (GMTs) of H5N1 HI Antibodies | A/Vietnam, Day 0 | 5.0 Titers |
| GSK1562902A V/V/6 Group | Geometric Mean Titers (GMTs) of H5N1 HI Antibodies | A/Vietnam, Day 0 | 5.3 Titers |
| GSK1562902A V/V/6 Group | Geometric Mean Titers (GMTs) of H5N1 HI Antibodies | A/Indonesia, Day 0 | 5.0 Titers |
| GSK1562902A 2V/I/6 Group | Geometric Mean Titers (GMTs) of H5N1 HI Antibodies | A/Indonesia, Day 0 | 5.0 Titers |
| GSK1562902A 2V/I/6 Group | Geometric Mean Titers (GMTs) of H5N1 HI Antibodies | A/Vietnam, Day 0 | 5.2 Titers |
| GSK1562902A 2V/V/6 Group | Geometric Mean Titers (GMTs) of H5N1 HI Antibodies | A/Indonesia, Day 0 | 5.0 Titers |
| GSK1562902A 2V/V/6 Group | Geometric Mean Titers (GMTs) of H5N1 HI Antibodies | A/Vietnam, Day 0 | 5.7 Titers |
Primary
Geometric Mean Titers (GMTs) of H5N1 HI Antibodies
GMTs were calculated for H5N1 HI antibodies against the A/Vietnam/1194/2004 or A/Indonesia/05/2005 strains, for the groups who received the booster dose at Month 6.
Time frame: At Month 6 + 7 Days
Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Geometric Mean Titers (GMTs) of H5N1 HI Antibodies | A/Vietnam, Month 6 + 7 days | 226.3 Titers |
| GSK1562902A V/I/6 Group | Geometric Mean Titers (GMTs) of H5N1 HI Antibodies | A/Indonesia, Month 6 + 7 days | 152.9 Titers |
| GSK1562902A V/V/6 Group | Geometric Mean Titers (GMTs) of H5N1 HI Antibodies | A/Indonesia, Month 6 + 7 days | 64.6 Titers |
| GSK1562902A V/V/6 Group | Geometric Mean Titers (GMTs) of H5N1 HI Antibodies | A/Vietnam, Month 6 + 7 days | 202.6 Titers |
| GSK1562902A 2V/I/6 Group | Geometric Mean Titers (GMTs) of H5N1 HI Antibodies | A/Vietnam, Month 6 + 7 days | 182.7 Titers |
| GSK1562902A 2V/I/6 Group | Geometric Mean Titers (GMTs) of H5N1 HI Antibodies | A/Indonesia, Month 6 + 7 days | 120.0 Titers |
| GSK1562902A 2V/V/6 Group | Geometric Mean Titers (GMTs) of H5N1 HI Antibodies | A/Indonesia, Month 6 + 7 days | 65.0 Titers |
| GSK1562902A 2V/V/6 Group | Geometric Mean Titers (GMTs) of H5N1 HI Antibodies | A/Vietnam, Month 6 + 7 days | 224.5 Titers |
Primary
Geometric Mean Titers (GMTs) of H5N1 HI Antibodies
GMTs were calculated for H5N1 HI antibodies against the A/Vietnam/1194/2004 or A/Indonesia/05/2005 strains, for the groups who received the booster dose at Month 6.
Time frame: At Month 6 + 21 Days
Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Geometric Mean Titers (GMTs) of H5N1 HI Antibodies | A/Indonesia, Month 6 + 21 Days | 303.4 Titers |
| GSK1562902A V/I/6 Group | Geometric Mean Titers (GMTs) of H5N1 HI Antibodies | A/Vietnam, Month 6 + 21 Days | 434.7 Titers |
| GSK1562902A V/V/6 Group | Geometric Mean Titers (GMTs) of H5N1 HI Antibodies | A/Vietnam, Month 6 + 21 Days | 287.2 Titers |
| GSK1562902A V/V/6 Group | Geometric Mean Titers (GMTs) of H5N1 HI Antibodies | A/Indonesia, Month 6 + 21 Days | 92.4 Titers |
| GSK1562902A 2V/I/6 Group | Geometric Mean Titers (GMTs) of H5N1 HI Antibodies | A/Indonesia, Month 6 + 21 Days | 392.9 Titers |
| GSK1562902A 2V/I/6 Group | Geometric Mean Titers (GMTs) of H5N1 HI Antibodies | A/Vietnam, Month 6 + 21 Days | 571.4 Titers |
| GSK1562902A 2V/V/6 Group | Geometric Mean Titers (GMTs) of H5N1 HI Antibodies | A/Indonesia, Month 6 + 21 Days | 127.7 Titers |
| GSK1562902A 2V/V/6 Group | Geometric Mean Titers (GMTs) of H5N1 HI Antibodies | A/Vietnam, Month 6 + 21 Days | 380.5 Titers |
Primary
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease
Booster SCR was defined as: For seronegative subjects at pre-booster (Month 6), antibody titer ≥ 1:40 at Month 6 + 7 days; For seropositive subjects at pre-booster (Month 6), antibody titer at Month 6 + 7 days ≥ 4 fold the pre-vaccination antibody titer at Month 6. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/5/2005, for adults who received the booster dose at Month 6.
Time frame: At Month 6 + 21 days
Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 21 Days | 51 Participants |
| GSK1562902A V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 21 Days | 51 Participants |
| GSK1562902A V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 21 Days | 42 Participants |
| GSK1562902A V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 21 Days | 39 Participants |
| GSK1562902A 2V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 21 Days | 44 Participants |
| GSK1562902A 2V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 21 Days | 45 Participants |
| GSK1562902A 2V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 21 Days | 38 Participants |
| GSK1562902A 2V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 21 Days | 39 Participants |
Primary
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease
Booster seroconversion (SCR) was defined as: For seronegative subjects at pre-booster (Month 6), antibody titer ≥ 1:40 at Month 6 + 7 days; For seropositive subjects at pre-booster (Month 6), antibody titer at Month 6 + 7 days ≥ 4 fold the pre-vaccination antibody titer at Month 6. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/5/2005, for adults who received the booster dose at Month 6.
Time frame: At Month 6 + 7 Days
Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 7 Days | 48 Participants |
| GSK1562902A V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 7 Days | 47 Participants |
| GSK1562902A V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 7 Days | 35 Participants |
| GSK1562902A V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 7 Days | 40 Participants |
| GSK1562902A 2V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 7 Days | 31 Participants |
| GSK1562902A 2V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 7 Days | 40 Participants |
| GSK1562902A 2V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 7 Days | 30 Participants |
| GSK1562902A 2V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 7 Days | 31 Participants |
Primary
Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease
A seroconverted (SCR) subject was defined as a vaccinated subject who had either a pre-vaccination titer \< 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and at least a four-fold increase in post-vaccination titer. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/5/2005, for adults who received the booster dose at Month 6.
Time frame: At Month 6 + 21 Days
Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 21 Days | 51 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 21 Days | 51 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 21 Days | 43 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 21 Days | 40 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 21 Days | 46 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 21 Days | 46 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 21 Days | 40 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 21 Days | 42 Participants |
Primary
Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease
A seroconverted (SCR) subject was defined as a vaccinated subject who had either a pre-vaccination titer \< 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and at least a four-fold increase in post-vaccination titer. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/5/2005, for adults who received the booster dose at Month 6.
Time frame: At Month 6 + 7 Days
Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 7 Days | 49 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 7 Days | 52 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 7 Days | 35 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 7 Days | 42 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 7 Days | 40 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 7 Days | 42 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 7 Days | 39 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 7 Days | 33 Participants |
Primary
Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease
A seroconverted (SCR) subject was defined as a vaccinated subject who had either a pre-vaccination titer \< 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and at least a four-fold increase in post-vaccination titer. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/5/2005, for adults who received the booster dose at Month 6.
Time frame: At Month 6
Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 | 14 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 | 0 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 | 6 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 | 5 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 | 26 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 | 27 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 | 2 Participants |
Primary
Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease
A seroprotected (SPR) subject was defined as a vaccinated subject with serum H5N1 HI titer ≥ 1:40. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/5/2005, for adults who received the booster dose at Month 6.
Time frame: At Month 6
Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 | 0 Participants |
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 | 14 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 | 7 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 | 5 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 | 26 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 | 2 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 | 28 Participants |
Primary
Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease
A seroprotected (SPR) subject was defined as a vaccinated subject with serum H5N1 HI titer ≥ 1:40. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/5/2005, for adults who received the booster dose at Month 6.
Time frame: At Month 6 + 21 Days
Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 21 Days | 51 Participants |
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 21 Days | 51 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 21 Days | 40 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 21 Days | 43 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 21 Days | 46 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 21 Days | 46 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 21 Days | 40 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 21 Days | 42 Participants |
Primary
Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease
A seroprotected (SPR) subject was defined as a vaccinated subject with serum H5N1 HI titer ≥ 1:40. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/5/2005, for adults who received the booster dose at Month 6.
Time frame: At Month 6 + 7 Days
Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 7 Days | 49 Participants |
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 7 Days | 52 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 7 Days | 42 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 7 Days | 35 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 7 Days | 40 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 7 Days | 42 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 7 Days | 33 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 7 Days | 40 Participants |
Primary
Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease
A seroprotected (SPR) subject was defined as a vaccinated subject with serum H5N1 HI titer ≥ 1:40. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/5/2005, for adults who received the booster dose at Month 6.
Time frame: At Day 0
Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Day 0 | 0 Participants |
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Day 0 | 0 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Day 0 | 0 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Day 0 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Day 0 | 1 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Day 0 | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Day 0 | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Day 0 | 2 Participants |
Primary
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Assessed solicited local symptoms were ecchymosis, induration, pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 ecchymosis/induration/redness/swelling = spreading beyond 100 millimeters (mm) of injection site.
Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses, up to 6/12 months + 7 days
Population: This analysis was performed on the Total vaccinated Cohort, which included all vaccinated subjects for whom data were available and who had their symptom sheets filled in. The data for Dose 3 were not collected from subjects who did not receive the booster dose, given at either Month 6 or Month 12.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Across doses | 11 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Ecchymosis, Across doses | 0 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Ecchymosis, Dose 2 | 1 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 46 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Induration, Across doses | 1 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Ecchymosis, Dose 2 | 0 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across doses | 6 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Across doses | 12 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Across doses | 0 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Ecchymosis, Dose 1 | 1 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Induration, Dose 2 | 1 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Induration, Dose 1 | 9 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 50 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Ecchymosis, Across doses | 2 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Induration, Across doses | 17 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Induration, Dose 1 | 0 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Induration, Dose 2 | 13 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 7 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 4 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 7 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Across doses | 56 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 9 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across doses | 1 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Ecchymosis, Dose 1 | 0 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 4 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 1 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 2 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 2 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Across doses | 15 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Ecchymosis, Across doses | 0 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across doses | 0 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Induration, Across doses | 13 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Ecchymosis, Dose 1 | 1 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 61 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Across doses | 0 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 12 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Across doses | 8 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Induration, Dose 1 | 0 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Induration, Dose 1 | 9 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 4 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 49 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Ecchymosis, Dose 2 | 0 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Induration, Across doses | 0 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Ecchymosis, Across doses | 1 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Induration, Dose 2 | 0 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Ecchymosis, Dose 1 | 0 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Ecchymosis, Dose 2 | 0 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Induration, Dose 2 | 11 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Across doses | 62 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 7 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across doses | 6 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 8 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 6 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Ecchymosis, Dose 3 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 3 | 15 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Ecchymosis, Dose 3 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 5 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 3 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 3 | 8 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Induration, Dose 3 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 3 | 53 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 3 | 5 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Ecchymosis, Dose 2 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Induration, Dose 3 | 16 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 3 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Ecchymosis, Across doses | 2 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across doses | 5 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Across doses | 16 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Across doses | 21 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across doses | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Ecchymosis, Dose 1 | 2 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Across doses | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Ecchymosis, Dose 1 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Induration, Dose 1 | 10 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Induration, Dose 1 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 54 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Ecchymosis, Dose 2 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 7 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Across doses | 61 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Induration, Dose 2 | 9 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Induration, Across doses | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Induration, Dose 2 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 50 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Induration, Across doses | 22 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 11 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Ecchymosis, Across doses | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 10 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 3 | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across doses | 10 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 14 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Induration, Dose 2 | 14 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Induration, Across doses | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Ecchymosis, Across doses | 1 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Ecchymosis, Dose 3 | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Induration, Dose 2 | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 3 | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 3 | 13 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 49 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Induration, Across doses | 25 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 8 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 4 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 3 | 51 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Ecchymosis, Dose 3 | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Induration, Dose 3 | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 3 | 5 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Induration, Dose 3 | 13 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Ecchymosis, Dose 1 | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 7 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Across doses | 13 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Induration, Dose 1 | 20 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Induration, Dose 1 | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Ecchymosis, Dose 1 | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 3 | 7 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 56 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Ecchymosis, Across doses | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Across doses | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 10 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 4 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Ecchymosis, Dose 2 | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Across doses | 59 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Ecchymosis, Dose 2 | 1 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Across doses | 22 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across doses | 0 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Across doses | 0 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 4 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Induration, Dose 2 | 0 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 54 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 5 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Ecchymosis, Dose 2 | 0 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Across doses | 61 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Ecchymosis, Dose 1 | 0 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across doses | 8 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Induration, Dose 1 | 0 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Across doses | 10 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Ecchymosis, Dose 2 | 0 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Induration, Dose 1 | 7 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 5 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across doses | 0 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Induration, Across doses | 0 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Induration, Across doses | 14 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 53 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Ecchymosis, Dose 1 | 0 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Induration, Dose 2 | 11 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 5 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 6 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 5 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Ecchymosis, Across doses | 0 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Ecchymosis, Across doses | 0 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Across doses | 8 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Across doses | 11 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Induration, Dose 1 | 9 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Induration, Dose 1 | 0 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Ecchymosis, Dose 2 | 2 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Ecchymosis, Dose 2 | 0 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Ecchymosis, Across doses | 2 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Induration, Across doses | 16 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Induration, Across doses | 0 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across doses | 8 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Ecchymosis, Dose 1 | 0 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Ecchymosis, Dose 1 | 0 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 52 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 5 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Across doses | 13 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across doses | 0 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Induration, Dose 2 | 11 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Induration, Dose 2 | 0 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 47 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 3 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 7 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 7 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 8 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Ecchymosis, Across doses | 0 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Across doses | 57 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Across doses | 0 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 10 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Induration, Across doses | 0 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 3 | 8 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 6 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 3 | 0 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Ecchymosis, Dose 3 | 0 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 3 | 0 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 4 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 7 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Ecchymosis, Across doses | 0 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 0 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 49 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Induration, Dose 2 | 0 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Induration, Dose 2 | 9 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across doses | 0 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Across doses | 16 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 2 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Ecchymosis, Dose 3 | 0 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Across doses | 62 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across doses | 5 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 57 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Induration, Dose 1 | 0 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Induration, Dose 1 | 14 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Across doses | 13 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Ecchymosis, Dose 1 | 0 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Ecchymosis, Dose 1 | 3 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Ecchymosis, Dose 2 | 1 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Across doses | 0 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Induration, Across doses | 24 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 8 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Ecchymosis, Across doses | 4 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 3 | 10 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Ecchymosis, Dose 2 | 0 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Induration, Dose 3 | 0 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 3 | 48 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 3 | 4 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Induration, Dose 3 | 15 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Induration, Dose 1 | 0 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Ecchymosis, Across doses | 0 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 3 | 8 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Induration, Dose 1 | 8 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Ecchymosis, Dose 3 | 0 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 3 | 44 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 3 | 0 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Ecchymosis, Dose 1 | 0 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 3 | 4 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 3 | 0 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Across doses | 15 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 10 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 9 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 1 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 8 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Ecchymosis, Dose 1 | 1 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Ecchymosis, Dose 3 | 0 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Ecchymosis, Across doses | 1 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 1 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 47 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 3 | 8 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Induration, Across doses | 19 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Induration, Dose 2 | 0 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Across doses | 1 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Induration, Dose 2 | 8 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Ecchymosis, Dose 2 | 0 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across doses | 0 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Across doses | 16 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Ecchymosis, Dose 2 | 0 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 1 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Induration, Dose 3 | 10 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Induration, Across doses | 0 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Across doses | 58 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 54 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 5 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across doses | 5 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Induration, Dose 3 | 0 Participants |
Primary
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Assessed solicited general symptoms were arthralgia, fatigue, fever \[defined as axillary temperature above (\>) 38 degrees Celsius (°C)\], headache, myalgia, shivering and sweating. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 40.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses, up to 12 months + 7 days
Population: This analysis was performed on the Total vaccinated Cohort, which included all vaccinated subjects for whom data were available and who had their symptom sheets filled in. The data for Dose 3 were not collected from subjects who did not receive the booster dose, given at either Month 6 or Month 12.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 2 | 10 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Dose 2 | 2 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia, Dose 1 | 7 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 2 | 1 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 21 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Across doses | 6 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 2 | 8 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 2 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 2 | 28 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 2 | 25 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Across doses | 6 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Dose 1 | 4 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Across doses | 13 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Across doses | 5 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 23 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Across doses | 6 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 1 | 3 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia, Dose 2 | 12 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Across doses | 34 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 1 | 29 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 2 | 3 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Across doses | 1 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 1 | 6 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 2 | 2 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 1 | 5 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Across doses | 22 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Across doses | 39 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 18 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 25 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 20 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 2 | 12 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 1 | 0 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Dose 2 | 0 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Across doses | 31 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Across doses | 0 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Dose 1 | 0 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia, Across doses | 16 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 22 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Arthralgia, Across doses | 17 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Across doses | 41 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia, Dose 2 | 1 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Across doses | 2 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Across doses | 35 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 0 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Dose 2 | 2 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 1 | 29 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia, Across doses | 3 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 3 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 1 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Across doses | 4 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Across doses | 15 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia, Dose 1 | 2 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 1 | 13 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 1 | 3 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Across doses | 21 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Arthralgia, Dose 1 | 8 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 1 | 13 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 2 | 14 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Dose 1 | 4 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 24 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Across doses | 33 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Arthralgia, Dose 2 | 12 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 22 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 2 | 27 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 1 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Across doses | 18 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 27 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia, Dose 1 | 1 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Arthralgia, Dose 1 | 12 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 1 | 29 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 22 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Arthralgia, Across doses | 25 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Dose 2 | 2 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia, Across doses | 2 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Across doses | 37 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 2 | 21 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 1 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia, Dose 2 | 1 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Across doses | 2 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Arthralgia, Dose 2 | 20 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Across doses | 34 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 1 | 11 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 1 | 1 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 1 | 12 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Across doses | 2 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 0 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Across doses | 41 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Across doses | 38 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 2 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 18 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Dose 1 | 3 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Across doses | 26 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Across doses | 4 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 1 | 7 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 2 | 1 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Across doses | 28 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 1 | 26 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 2 | 2 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Dose 2 | 2 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 2 | 32 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 1 | 1 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Across doses | 15 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Dose 1 | 0 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia, Across doses | 22 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 24 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 2 | 9 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Dose 1 | 3 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Across doses | 4 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 19 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 25 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Across doses | 0 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Across doses | 31 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia, Dose 1 | 12 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 15 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 2 | 19 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 2 | 12 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Across doses | 3 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 27 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Across doses | 3 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia, Dose 2 | 16 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Across doses | 1 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 2 | 2 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 1 | 7 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Across doses | 28 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 1 | 0 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Dose 2 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Across doses | 3 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 3 | 35 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Across doses | 1 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Across doses | 41 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Across doses | 36 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 2 | 12 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Across doses | 3 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Across doses | 24 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Across doses | 2 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Dose 2 | 1 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 2 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 25 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 2 | 12 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 2 | 1 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 18 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Arthralgia, Dose 3 | 18 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 28 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia, Dose 3 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 2 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia, Dose 2 | 9 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Dose 3 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 1 | 8 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Dose 3 | 2 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 3 | 30 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 2 | 27 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 1 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 3 | 1 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 1 | 9 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 3 | 17 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 3 | 3 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 2 | 9 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 1 | 8 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 3 | 15 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 1 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 3 | 13 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Dose 1 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia, Across doses | 26 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 18 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Dose 1 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Across doses | 4 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 20 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia, Dose 1 | 9 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Across doses | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 3 | 31 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 3 | 2 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 3 | 11 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Across doses | 23 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Across doses | 42 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 24 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Across doses | 46 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 3 | 1 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 1 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 2 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 3 | 28 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 3 | 22 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 1 | 10 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Dose 3 | 3 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Arthralgia, Dose 1 | 11 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia, Dose 1 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 2 | 10 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Across doses | 1 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 3 | 32 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 1 | 29 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia, Dose 3 | 17 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Dose 1 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia, Across doses | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Dose 2 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Dose 2 | 1 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Across doses | 21 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Across doses | 45 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 24 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Across doses | 21 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia, Dose 2 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Across doses | 47 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 3 | 2 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Across doses | 3 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 1 | 31 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Arthralgia, Across doses | 27 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Arthralgia, Dose 2 | 11 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 19 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 2 | 23 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 4 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia, Dose 3 | 16 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 3 | 30 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 3 | 3 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 3 | 27 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Dose 3 | 3 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 3 | 2 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 3 | 12 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Arthralgia, Across doses | 28 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Across doses | 44 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Across doses | 3 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Across doses | 38 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Across doses | 41 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Across doses | 8 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Across doses | 48 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Across doses | 47 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Across doses | 34 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Across doses | 20 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Across doses | 17 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Arthralgia, Dose 1 | 15 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia, Dose 1 | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 26 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Dose 1 | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 25 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 1 | 30 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 1 | 21 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 1 | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Arthralgia, Dose 2 | 13 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia, Dose 2 | 1 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Dose 2 | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Dose 2 | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 26 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 3 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 1 | 32 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 2 | 21 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 2 | 13 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 19 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 3 | 26 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Dose 1 | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 2 | 1 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 2 | 13 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 2 | 5 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 2 | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 2 | 4 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Arthralgia, Dose 3 | 19 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia, Dose 3 | 3 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Dose 3 | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Dose 3 | 3 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 3 | 28 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 3 | 4 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 3 | 19 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 3 | 4 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 3 | 17 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 3 | 13 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia, Across doses | 4 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia, Across doses | 25 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Across doses | 4 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Across doses | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Across doses | 3 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Across doses | 38 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Across doses | 4 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Across doses | 36 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Across doses | 5 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Across doses | 3 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 3 | 36 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 3 | 3 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 3 | 33 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia, Dose 1 | 12 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 20 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Dose 1 | 1 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 1 | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 1 | 19 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 1 | 12 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 1 | 1 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 1 | 10 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia, Dose 2 | 12 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 21 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 21 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Dose 2 | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 22 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 2 | 22 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 2 | 1 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 23 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Across doses | 22 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia, Dose 2 | 14 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Across doses | 0 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 2 | 17 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 1 | 14 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 27 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 2 | 1 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 30 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Across doses | 4 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 2 | 3 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 1 | 2 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia, Across doses | 3 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Across doses | 30 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Dose 2 | 4 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Dose 1 | 0 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Dose 1 | 0 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 1 | 31 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 2 | 4 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia, Across doses | 20 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Across doses | 4 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 28 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 2 | 40 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 2 | 13 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Dose 1 | 0 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 1 | 5 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia, Dose 1 | 13 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 2 | 12 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 1 | 0 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Across doses | 1 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Across doses | 4 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Across doses | 4 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 1 | 5 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 24 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Across doses | 36 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Arthralgia, Across doses | 20 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Across doses | 16 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Across doses | 45 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 27 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 1 | 0 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Across doses | 31 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Across doses | 22 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 1 | 15 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 5 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 2 | 37 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Dose 2 | 4 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Across doses | 1 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Across doses | 37 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 2 | 17 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 1 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 17 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia, Dose 2 | 1 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Dose 2 | 0 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 18 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Arthralgia, Dose 1 | 13 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 0 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Across doses | 5 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 1 | 30 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Arthralgia, Dose 2 | 14 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Across doses | 49 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Across doses | 15 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 0 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia, Dose 1 | 2 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Dose 2 | 2 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 1 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 22 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Across doses | 3 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 21 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 2 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Arthralgia, Dose 1 | 9 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Across doses | 6 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia, Dose 1 | 0 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Across doses | 7 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 1 | 27 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Across doses | 34 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 1 | 8 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Across doses | 19 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 2 | 26 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 1 | 0 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Across doses | 31 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 2 | 14 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Across doses | 4 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Arthralgia, Dose 2 | 12 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Dose 1 | 0 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia, Dose 2 | 1 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 1 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Across doses | 33 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 3 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Across doses | 39 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Dose 2 | 0 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 24 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Arthralgia, Across doses | 13 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Across doses | 2 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 19 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 21 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 22 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 2 | 1 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia, Across doses | 12 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 2 | 2 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Dose 2 | 3 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 2 | 6 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Dose 1 | 1 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Across doses | 3 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Across doses | 19 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Across doses | 41 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Across doses | 30 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 20 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 22 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia, Across doses | 1 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Dose 1 | 0 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 1 | 29 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 2 | 14 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 2 | 30 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 1 | 1 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 1 | 8 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Across doses | 2 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Across doses | 0 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 1 | 2 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 1 | 0 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia, Dose 1 | 8 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 2 | 2 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 1 | 1 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia, Dose 2 | 11 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Across doses | 4 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Across doses | 1 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 2 | 6 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Across doses | 45 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 2 | 10 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 1 | 6 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 16 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia, Dose 2 | 13 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 3 | 18 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 18 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Across doses | 25 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Across doses | 3 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia, Dose 3 | 4 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 1 | 5 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 3 | 20 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 3 | 28 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Dose 1 | 1 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 3 | 23 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 2 | 2 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Across doses | 7 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 21 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 1 | 0 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 2 | 3 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Dose 3 | 3 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Arthralgia, Dose 3 | 19 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Dose 3 | 0 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 3 | 31 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 2 | 8 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 2 | 2 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 1 | 4 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia, Dose 2 | 3 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia, Dose 1 | 6 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 2 | 12 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Dose 3 | 3 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Across doses | 4 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Dose 1 | 0 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Dose 2 | 1 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 1 | 27 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia, Across doses | 25 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia, Across doses | 5 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 3 | 11 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 3 | 4 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 19 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Across doses | 23 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 0 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 1 | 2 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Across doses | 4 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 3 | 17 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Across doses | 0 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 3 | 2 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 2 | 29 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 3 | 1 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 2 | 28 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 1 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Across doses | 21 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 0 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Arthralgia, Dose 2 | 15 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 3 | 10 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Arthralgia, Dose 1 | 8 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Dose 1 | 1 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Across doses | 47 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 3 | 0 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 3 | 1 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 28 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Dose 2 | 0 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 2 | 9 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia, Dose 3 | 17 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 3 | 24 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 3 | 29 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Across doses | 2 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Across doses | 45 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Arthralgia, Across doses | 29 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 1 | 9 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Across doses | 23 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 25 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 4 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Across doses | 40 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Dose 2 | 1 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 1 | 26 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 20 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 1 | 0 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Across doses | 4 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 23 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia, Dose 1 | 1 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Across doses | 43 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Across doses | 41 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Across doses | 4 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Across doses | 24 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 25 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Across doses | 29 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 0 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Dose 1 | 0 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Across doses | 4 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Dose 1 | 2 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 3 | 29 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 20 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Across doses | 35 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 1 | 29 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Across doses | 41 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 1 | 14 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Across doses | 42 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 1 | 1 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 1 | 12 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Across doses | 2 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Arthralgia, Dose 2 | 15 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Across doses | 44 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 2 | 25 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 0 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia, Across doses | 24 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 19 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Arthralgia, Across doses | 26 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia, Dose 3 | 13 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Dose 2 | 0 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Dose 2 | 2 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 3 | 13 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 3 | 0 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 2 | 14 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 15 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 3 | 15 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 3 | 28 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 3 | 2 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Arthralgia, Dose 1 | 6 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 3 | 2 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Across doses | 3 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Across doses | 1 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 3 | 25 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 13 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 3 | 29 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Across doses | 0 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 3 | 2 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia, Dose 1 | 0 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Across doses | 5 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 2 | 0 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia, Dose 1 | 6 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 2 | 2 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 23 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Dose 1 | 2 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia, Across doses | 2 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 1 | 31 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 3 | 21 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 1 | 0 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 3 | 3 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 1 | 13 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 3 | 21 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 3 | 27 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 2 | 28 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 1 | 12 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 3 | 32 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 1 | 1 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever, Dose 3 | 0 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia, Dose 2 | 1 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Dose 3 | 2 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia, Dose 3 | 1 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 1 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia, Dose 2 | 14 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Arthralgia, Dose 3 | 14 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 2 | 6 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 27 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 2 | 0 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Dose 3 | 2 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 26 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 2 | 7 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever, Dose 2 | 2 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 0 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 2 | 14 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Across doses | 4 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Across doses | 43 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Across doses | 47 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Across doses | 29 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Across doses | 25 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever, Across doses | 5 Participants |
Primary
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Time frame: During the 30-day (Days 0-29) post-primary vaccination period (Month 6 + 30 days)
Population: This analysis was performed on the Total vaccinated Cohort, which included all vaccinated subjects for whom data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Any AEs | 31 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Related AEs | 12 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Grade 3 AEs | 3 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Related AEs | 11 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Any AEs | 19 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Grade 3 AEs | 4 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Related AEs | 11 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Any AEs | 32 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Grade 3 AEs | 2 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Any AEs | 28 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Grade 3 AEs | 3 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Related AEs | 15 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Any AEs | 18 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Grade 3 AEs | 0 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Related AEs | 5 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Grade 3 AEs | 2 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Any AEs | 10 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Related AEs | 3 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Grade 3 AEs | 1 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Any AEs | 19 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Related AEs | 6 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Any AEs | 24 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Grade 3 AEs | 7 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Related AEs | 6 Participants |
Primary
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Time frame: During the 30-day (Days 0-29) post-booster vaccination period (Month 12 + 30 days)
Population: This analysis was performed on the Total vaccinated Cohort, which included all vaccinated subjects for whom data were available. Data were collected only for subjects who received the Month 12 vaccine dose.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Any AE(s) | 16 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Grade 3 AE(s) | 2 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Related AE(s) | 7 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Any AE(s) | 10 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Related AE(s) | 4 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Grade 3 AE(s) | 2 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Grade 3 AE(s) | 2 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Related AE(s) | 9 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Any AE(s) | 16 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Grade 3 AE(s) | 1 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Any AE(s) | 14 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Related AE(s) | 9 Participants |
Primary
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Time frame: During the entire study period (Day 0 to Month 18)
Population: This analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects for whom data were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| GSK1562902A V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | 35 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | 23 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | 32 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | 31 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | 27 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | 24 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | 30 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | 31 Participants |
Primary
Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value
The seropositivity cut-off for the assay was an antibody titer equal to or above (≥) 1:10, in the sera of subjects seronegative before vaccination. The flu strains assessed were A/Indonesia/05/2005 and A/Vietnam/1194/2004, for adults who received the booster dose at Month 6.
Time frame: At Month 6
Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value | A/Vietnam, Month 6 | 25 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value | A/Indonesia, Month 6 | 4 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value | A/Indonesia, Month 6 | 2 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value | A/Vietnam, Month 6 | 18 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value | A/Indonesia, Month 6 | 18 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value | A/Vietnam, Month 6 | 35 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value | A/Vietnam, Month 6 | 34 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value | A/Indonesia, Month 6 | 13 Participants |
Primary
Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value
The seropositivity cut-off for the assay was an antibody titer equal to or above (≥) 1:10, in the sera of subjects seronegative before vaccination. The flu strains assessed were A/Indonesia/05/2005 and A/Vietnam/1194/2004, for adults who received the booster dose at Month 6.
Time frame: At Day 0
Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value | A/Vietnam, Day 0 | 0 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value | A/Indonesia, Day 0 | 0 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value | A/Indonesia, Day 0 | 0 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value | A/Vietnam, Day 0 | 2 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value | A/Vietnam, Day 0 | 1 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value | A/Indonesia, Day 0 | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value | A/Vietnam, Day 0 | 2 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value | A/Indonesia, Day 0 | 0 Participants |
Primary
Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value
The seropositivity cut-off for the assay was an antibody titer equal to or above (≥) 1:10, in the sera of subjects seronegative before vaccination. The flu strains assessed were A/Indonesia/05/2005 and A/Vietnam/1194/2004, for adults who received the booster dose at Month 6.
Time frame: At Month 6 + 21 Days
Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value | A/Indonesia, Month 6 + 21 Days | 51 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value | A/Vietnam, Month 6 + 21 Days | 51 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value | A/Vietnam, Month 6 + 21 Days | 43 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value | A/Indonesia, Month 6 + 21 Days | 41 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value | A/Vietnam, Month 6 + 21 Days | 47 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value | A/Indonesia, Month 6 + 21 Days | 47 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value | A/Indonesia, Month 6 + 21 Days | 41 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value | A/Vietnam, Month 6 + 21 Days | 43 Participants |
Primary
Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value
The seropositivity cut-off for the assay was an antibody titer equal to or above (≥) 1:10, in the sera of subjects seronegative before vaccination. The flu strains assessed were A/Indonesia/05/2005 and A/Vietnam/1194/2004, for adults who received the booster dose at Month 6.
Time frame: At Month 6 + 7 Days
Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value | A/Indonesia, Month 6 + 7 Days | 52 Participants |
| GSK1562902A V/I/6 Group | Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value | A/Vietnam, Month 6 + 7 Days | 52 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value | A/Vietnam, Month 6 + 7 Days | 42 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value | A/Indonesia, Month 6 + 7 Days | 37 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value | A/Indonesia, Month 6 + 7 Days | 41 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value | A/Vietnam, Month 6 + 7 Days | 43 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value | A/Indonesia, Month 6 + 7 Days | 37 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value | A/Vietnam, Month 6 + 7 Days | 41 Participants |
Primary
Number of Subjects With Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: During the entire study period (Day 0 to Month 18)
Population: This analysis was performed on the Total vaccinated Cohort, which included all vaccinated subjects for whom data were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| GSK1562902A V/I/6 Group | Number of Subjects With Serious Adverse Events (SAEs) | 4 Participants |
| GSK1562902A V/V/6 Group | Number of Subjects With Serious Adverse Events (SAEs) | 1 Participants |
| GSK1562902A 2V/I/6 Group | Number of Subjects With Serious Adverse Events (SAEs) | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Subjects With Serious Adverse Events (SAEs) | 3 Participants |
| GSK1562902A V/I/12 Group | Number of Subjects With Serious Adverse Events (SAEs) | 1 Participants |
| GSK1562902A V/V/12 Group | Number of Subjects With Serious Adverse Events (SAEs) | 5 Participants |
| GSK1562902A 2V/I/12 Group | Number of Subjects With Serious Adverse Events (SAEs) | 1 Participants |
| GSK1562902A 2V/V/12 Group | Number of Subjects With Serious Adverse Events (SAEs) | 3 Participants |
Primary
Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease
The seroconversion factor (SCF) was defined as the fold change in serum H5N1 HI geometric mean titers (GMTs) post-vaccination compared to Day 0. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/5/2005, for adults who received the booster dose at Month 6.
Time frame: At Month 6
Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 | 2.4 Fold Increase |
| GSK1562902A V/I/6 Group | Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 | 1.1 Fold Increase |
| GSK1562902A V/V/6 Group | Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 | 1.1 Fold Increase |
| GSK1562902A V/V/6 Group | Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 | 1.8 Fold Increase |
| GSK1562902A 2V/I/6 Group | Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 | 6.0 Fold Increase |
| GSK1562902A 2V/I/6 Group | Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 | 1.7 Fold Increase |
| GSK1562902A 2V/V/6 Group | Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 | 5.6 Fold Increase |
| GSK1562902A 2V/V/6 Group | Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 | 1.4 Fold Increase |
Primary
Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease
The seroconversion factor (SCF) was defined as the fold change in serum H5N1 HI geometric mean titers (GMTs) post vaccination compared to Day 0. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/5/2005, for adults who received the booster dose at Month 6.
Time frame: At Month 6 + 21 Days
Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 21 Days | 60.7 Fold Increase |
| GSK1562902A V/I/6 Group | Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 21 Days | 86.9 Fold Increase |
| GSK1562902A V/V/6 Group | Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 21 Days | 54.2 Fold Increase |
| GSK1562902A V/V/6 Group | Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 21 Days | 18.5 Fold Increase |
| GSK1562902A 2V/I/6 Group | Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 21 Days | 78.6 Fold Increase |
| GSK1562902A 2V/I/6 Group | Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 21 Days | 114.3 Fold Increase |
| GSK1562902A 2V/V/6 Group | Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 21 Days | 25.5 Fold Increase |
| GSK1562902A 2V/V/6 Group | Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 21 Days | 66.0 Fold Increase |
Primary
Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease
The seroconversion factor (SCF) was defined as the fold change in serum H5N1 HI geometric mean titers (GMTs) post-vaccination compared to Day 0. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/5/2005, for adults who received the booster dose at Month 6.
Time frame: At Month 6 + 7 Days
Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 7 Days | 45.3 Fold Increase |
| GSK1562902A V/I/6 Group | Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 7 Days | 30.6 Fold Increase |
| GSK1562902A V/V/6 Group | Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 7 Days | 38.2 Fold Increase |
| GSK1562902A V/V/6 Group | Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 7 Days | 12.9 Fold Increase |
| GSK1562902A 2V/I/6 Group | Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 7 Days | 36.5 Fold Increase |
| GSK1562902A 2V/I/6 Group | Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 7 Days | 24.0 Fold Increase |
| GSK1562902A 2V/V/6 Group | Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Indonesia, Month 6 + 7 Days | 13.0 Fold Increase |
| GSK1562902A 2V/V/6 Group | Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | A/Vietnam, Month 6 + 7 Days | 38.8 Fold Increase |
Secondary
Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12
Booster Factor (Seroconversion Factor booster) was defined as the fold change in H5N1 HI antibodies between the pre- and post-booster vaccination time-points (mean\[log10(POST/M12)\]). The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/05/2005, for groups who received the booster dose at Month 12.
Time frame: At Month 12 + 7 Days and at Month 12 + 21 Days
Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 33.1 Fold Increase |
| GSK1562902A V/I/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 70.9 Fold Increase |
| GSK1562902A V/I/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 35.2 Fold Increase |
| GSK1562902A V/I/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 65.8 Fold Increase |
| GSK1562902A V/V/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 23.8 Fold Increase |
| GSK1562902A V/V/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 27.5 Fold Increase |
| GSK1562902A V/V/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 41.1 Fold Increase |
| GSK1562902A V/V/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 16.7 Fold Increase |
| GSK1562902A 2V/I/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 21.9 Fold Increase |
| GSK1562902A 2V/I/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 75.8 Fold Increase |
| GSK1562902A 2V/I/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 57.6 Fold Increase |
| GSK1562902A 2V/I/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 29.1 Fold Increase |
| GSK1562902A 2V/V/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 30.2 Fold Increase |
| GSK1562902A 2V/V/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 33.7 Fold Increase |
| GSK1562902A 2V/V/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 18.7 Fold Increase |
| GSK1562902A 2V/V/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 17.6 Fold Increase |
Secondary
Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12
Booster Factor (Seroconversion Factor booster) was defined as the fold change in H5N1 HI antibodies between the pre- and post-booster vaccination time-points (mean\[log10(POST/M12)\]). The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/05/2005, for groups who received the booster dose at Month 12.
Time frame: At Month 12 + 7 Days, Month 12 + 21 Days and at Month 18
Population: The analysis was performed on the ATP Cohort for persistence, which included all evaluable subjects for whom long term immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 35.2 Fold Increase |
| GSK1562902A V/I/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 78.7 Fold Increase |
| GSK1562902A V/I/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 18 | 25.1 Fold Increase |
| GSK1562902A V/I/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 37.9 Fold Increase |
| GSK1562902A V/I/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 73.6 Fold Increase |
| GSK1562902A V/I/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 18 | 12.0 Fold Increase |
| GSK1562902A V/V/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 18 | 10.2 Fold Increase |
| GSK1562902A V/V/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 28.9 Fold Increase |
| GSK1562902A V/V/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 16.8 Fold Increase |
| GSK1562902A V/V/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 18 | 10.3 Fold Increase |
| GSK1562902A V/V/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 23.6 Fold Increase |
| GSK1562902A V/V/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 43.1 Fold Increase |
| GSK1562902A 2V/I/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 76.2 Fold Increase |
| GSK1562902A 2V/I/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 18 | 44.5 Fold Increase |
| GSK1562902A 2V/I/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 19.9 Fold Increase |
| GSK1562902A 2V/I/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 18 | 18.6 Fold Increase |
| GSK1562902A 2V/I/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 55.7 Fold Increase |
| GSK1562902A 2V/I/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 27.9 Fold Increase |
| GSK1562902A 2V/V/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 30.2 Fold Increase |
| GSK1562902A 2V/V/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 18 | 10.2 Fold Increase |
| GSK1562902A 2V/V/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 33.7 Fold Increase |
| GSK1562902A 2V/V/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 17.6 Fold Increase |
| GSK1562902A 2V/V/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 18.7 Fold Increase |
| GSK1562902A 2V/V/6 Group | Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 18 | 21.3 Fold Increase |
Secondary
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12
Among cytokines expressed after background reduction were cluster of differentiation 4 all doubles (CD4 All Doubles), cluster of differentiation 40-ligand (CD40-L), interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α). The 2 flu strains assessed were A/Indonesia/05/2005 and A/Vietnam/1194/2004.
Time frame: At Day 0, Month 6, Month 12, Month 12 + 7 Days, Month 12 + 21 Days and Month 18
Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Vietnam, Month 12 + 7 Days | 1131.19 cells/million T-cells | Standard Deviation 1352.73 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Vietnam, Month 12 + 21 Days | 14.75 cells/million T-cells | Standard Deviation 282.33 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Indonesia, Month 12 + 21 Days | 48.83 cells/million T-cells | Standard Deviation 375.84 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Vietnam, Month 12 | 9.12 cells/million T-cells | Standard Deviation 276.25 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Indonesia, Month 12 + 7 Days | 973.45 cells/million T-cells | Standard Deviation 756.29 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Vietnam, Month 12 + 7 Days | 10.89 cells/million T-cells | Standard Deviation 363.87 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Indonesia, Month 12 + 7 Days | 54.30 cells/million T-cells | Standard Deviation 362.16 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Indonesia, Month 12 + 7 Days | 55.96 cells/million T-cells | Standard Deviation 393.8 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Indonesia, Month 12 + 7 Days | 68.32 cells/million T-cells | Standard Deviation 385.82 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Vietnam, Month 12 | 8.92 cells/million T-cells | Standard Deviation 240.77 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Indonesia, Month 12 | 29.30 cells/million T-cells | Standard Deviation 263.6 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Vietnam, Month 12 + 7 Days | 20.48 cells/million T-cells | Standard Deviation 385.51 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Vietnam, Month 18 | 1499.43 cells/million T-cells | Standard Deviation 1302.01 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Vietnam, Month 6 | 31.78 cells/million T-cells | Standard Deviation 296.04 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Vietnam, Day 0 | 24.58 cells/million T-cells | Standard Deviation 437.31 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Indonesia, Month 12 + 21 Days | 62.99 cells/million T-cells | Standard Deviation 387.92 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Vietnam, Month 12 | 729.77 cells/million T-cells | Standard Deviation 345.26 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Vietnam, Month 18 | 13.33 cells/million T-cells | Standard Deviation 342.9 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Indonesia, Month 18 | 8.53 cells/million T-cells | Standard Deviation 121.12 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Vietnam, Month 12 + 21 Days | 12.52 cells/million T-cells | Standard Deviation 278.19 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Indonesia, Month 12 | 716.74 cells/million T-cells | Standard Deviation 400.83 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Vietnam, Month 12 + 21 Days | 11.90 cells/million T-cells | Standard Deviation 273.59 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Indonesia, Month 12 + 21 Days | 13.88 cells/million T-cells | Standard Deviation 121.34 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Indonesia, Month 18 | 45.30 cells/million T-cells | Standard Deviation 266.64 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Vietnam, Month 12 + 7 Days | 18.73 cells/million T-cells | Standard Deviation 398.89 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Vietnam, Month 12 + 7 Days | 7.58 cells/million T-cells | Standard Deviation 253.61 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Indonesia, Month 12 + 7 Days | 13.38 cells/million T-cells | Standard Deviation 163.26 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Vietnam, Month 18 | 15.35 cells/million T-cells | Standard Deviation 281.28 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Indonesia, Month 12 + 21 Days | 2047.96 cells/million T-cells | Standard Deviation 1439.33 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Vietnam, Month 12 | 5.79 cells/million T-cells | Standard Deviation 214.35 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Indonesia, Month 12 | 10.22 cells/million T-cells | Standard Deviation 195.65 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Vietnam, Day 0 | 38.69 cells/million T-cells | Standard Deviation 468.52 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Vietnam, Month 6 | 690.45 cells/million T-cells | Standard Deviation 600.77 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Vietnam, Month 6 | 31.09 cells/million T-cells | Standard Deviation 359.03 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Vietnam, Day 0 | 410.28 cells/million T-cells | Standard Deviation 363.5 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Indonesia, Month 12 + 21 Days | 59.21 cells/million T-cells | Standard Deviation 402.04 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Vietnam, Month 12 | 886.76 cells/million T-cells | Standard Deviation 457.39 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Vietnam, Month 18 | 1869.31 cells/million T-cells | Standard Deviation 1525.68 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Indonesia, Month 18 | 1703.60 cells/million T-cells | Standard Deviation 838.53 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Vietnam, Month 12 + 21 Days | 16.35 cells/million T-cells | Standard Deviation 341.81 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Indonesia, Month 12 | 1020.53 cells/million T-cells | Standard Deviation 642.48 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Vietnam, Month 12 + 21 Days | 2268.27 cells/million T-cells | Standard Deviation 1995.17 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Indonesia, Month 12 + 21 Days | 2392.88 cells/million T-cells | Standard Deviation 1398.76 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Indonesia, Month 18 | 45.87 cells/million T-cells | Standard Deviation 268.24 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Vietnam, Day 0 | 33.23 cells/million T-cells | Standard Deviation 473.07 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Vietnam, Month 12 + 7 Days | 1897.17 cells/million T-cells | Standard Deviation 2415.04 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Indonesia, Month 12 + 7 Days | 1498.36 cells/million T-cells | Standard Deviation 1396.73 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Vietnam, Month 18 | 27.14 cells/million T-cells | Standard Deviation 378.73 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Indonesia, Month 18 | 1461.90 cells/million T-cells | Standard Deviation 863.23 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Vietnam, Month 12 | 992.70 cells/million T-cells | Standard Deviation 427.17 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Indonesia, Month 12 | 1149.50 cells/million T-cells | Standard Deviation 571.65 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Vietnam, Day 0 | 3.05 cells/million T-cells | Standard Deviation 54.73 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Vietnam, Month 6 | 886.97 cells/million T-cells | Standard Deviation 662.75 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Vietnam, Month 6 | 1097.97 cells/million T-cells | Standard Deviation 712.55 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Vietnam, Day 0 | 376.07 cells/million T-cells | Standard Deviation 336.28 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Vietnam, Month 6 | 2.59 cells/million T-cells | Standard Deviation 24.33 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Vietnam, Day 0 | 355.17 cells/million T-cells | Standard Deviation 302.08 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Vietnam, Month 18 | 2174.81 cells/million T-cells | Standard Deviation 1734.47 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Indonesia, Month 18 | 1943.30 cells/million T-cells | Standard Deviation 922.92 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Indonesia, Month 12 | 2.09 cells/million T-cells | Standard Deviation 28.38 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Vietnam, Month 6 | 56.22 cells/million T-cells | Standard Deviation 359.78 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Vietnam, Month 12 + 21 Days | 2583.09 cells/million T-cells | Standard Deviation 2102.23 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Indonesia, Month 12 + 21 Days | 2744.31 cells/million T-cells | Standard Deviation 1545.16 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Vietnam, Month 12 | 2.33 cells/million T-cells | Standard Deviation 34.71 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Vietnam, Month 12 + 21 Days | 1833.81 cells/million T-cells | Standard Deviation 2015.18 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Vietnam, Month 12 + 7 Days | 2179.65 cells/million T-cells | Standard Deviation 2615.03 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Indonesia, Month 12 + 7 Days | 1968.90 cells/million T-cells | Standard Deviation 1594.19 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Indonesia, Month 12 + 7 Days | 8.21 cells/million T-cells | Standard Deviation 51.25 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Vietnam, Month 18 | 1309.65 cells/million T-cells | Standard Deviation 1177.92 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Vietnam, Month 12 | 1189.38 cells/million T-cells | Standard Deviation 519.31 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Indonesia, Month 12 | 1361.91 cells/million T-cells | Standard Deviation 670.66 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Vietnam, Month 12 + 7 Days | 4.40 cells/million T-cells | Standard Deviation 30.87 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Indonesia, Month 18 | 1113.27 cells/million T-cells | Standard Deviation 598.27 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Vietnam, Month 6 | 1272.27 cells/million T-cells | Standard Deviation 819.74 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Vietnam, Day 0 | 536.99 cells/million T-cells | Standard Deviation 406.96 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Indonesia, Month 12 + 21 Days | 5.43 cells/million T-cells | Standard Deviation 73.31 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Indonesia, Month 12 | 41.20 cells/million T-cells | Standard Deviation 285.4 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Vietnam, Month 18 | 2230.56 cells/million T-cells | Standard Deviation 1780.46 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Indonesia, Month 18 | 2003.28 cells/million T-cells | Standard Deviation 964.77 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Vietnam, Month 12 + 21 Days | 3.96 cells/million T-cells | Standard Deviation 67.7 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Vietnam, Month 12 + 7 Days | 1289.39 cells/million T-cells | Standard Deviation 2162.71 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Vietnam, Month 12 + 21 Days | 2651.19 cells/million T-cells | Standard Deviation 2181.61 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Indonesia, Month 12 + 21 Days | 2837.94 cells/million T-cells | Standard Deviation 1587.84 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Indonesia, Month 18 | 3.52 cells/million T-cells | Standard Deviation 49.19 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Vietnam, Month 12 + 21 Days | 1278.22 cells/million T-cells | Standard Deviation 1209.43 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Vietnam, Month 12 + 7 days | 2278.65 cells/million T-cells | Standard Deviation 2822.4 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Indonesia, Month 12 + 7 Days | 1979.02 cells/million T-cells | Standard Deviation 1644.97 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Vietnam, Month 18 | 4.32 cells/million T-cells | Standard Deviation 59.02 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Indonesia, Month 12 + 21 Days | 1245.91 cells/million T-cells | Standard Deviation 936.91 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Vietnam, Month 12 | 1230.51 cells/million T-cells | Standard Deviation 523.55 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Indonesia, Month 12 | 1379.04 cells/million T-cells | Standard Deviation 701.03 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Vietnam, Day 0 | 18.34 cells/million T-cells | Standard Deviation 169.79 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Vietnam, Month 12 | 14.72 cells/million T-cells | Standard Deviation 293.17 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Vietnam, Month 6 | 1296.63 cells/million T-cells | Standard Deviation 839.72 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Vietnam, Day 0 | 560.41 cells/million T-cells | Standard Deviation 427.07 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Vietnam, Month 6 | 24.13 cells/million T-cells | Standard Deviation 246.71 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Indonesia, Month 12 + 7 Days | 1198.25 cells/million T-cells | Standard Deviation 1200.42 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Vietnam, Month 18 | 16.41 cells/million T-cells | Standard Deviation 310.32 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Indonesia, Month 18 | 41.13 cells/million T-cells | Standard Deviation 261.84 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Indonesia, Month 12 | 29.84 cells/million T-cells | Standard Deviation 250.29 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Vietnam, Month 12 + 21 Days | 1428.02 cells/million T-cells | Standard Deviation 1030.82 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Indonesia, Month 18 | 1009.39 cells/million T-cells | Standard Deviation 1077.18 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Vietnam, Month 18 | 1250.85 cells/million T-cells | Standard Deviation 1843.92 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Vietnam, Day 0 | 30.79 cells/million T-cells | Standard Deviation 332.9 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Vietnam, Month 6 | 60.15 cells/million T-cells | Standard Deviation 348.65 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Indonesia, Month 12 | 19.96 cells/million T-cells | Standard Deviation 258.08 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Vietnam, Month 12 | 13.96 cells/million T-cells | Standard Deviation 149.1 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Indonesia, Month 12 + 7 Days | 48.09 cells/million T-cells | Standard Deviation 292.33 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Vietnam, Month 12 + 7 Days | 23.11 cells/million T-cells | Standard Deviation 409.7 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Indonesia, Month 12 + 21 Days | 22.21 cells/million T-cells | Standard Deviation 196.85 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Vietnam, Month 12 + 21 Days | 10.06 cells/million T-cells | Standard Deviation 260.79 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Indonesia, Month 18 | 36.98 cells/million T-cells | Standard Deviation 349.38 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Vietnam, Month 18 | 17.52 cells/million T-cells | Standard Deviation 231.65 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Vietnam, Day 0 | 3.22 cells/million T-cells | Standard Deviation 55.84 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Vietnam, Month 6 | 3.07 cells/million T-cells | Standard Deviation 55.8 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Indonesia, Month 12 | 3.66 cells/million T-cells | Standard Deviation 26.9 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Vietnam, Month 12 | 2.47 cells/million T-cells | Standard Deviation 32.62 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Indonesia, Month 12 + 7 Days | 7.68 cells/million T-cells | Standard Deviation 119.95 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Vietnam, Month 12 + 7 Days | 2.90 cells/million T-cells | Standard Deviation 183.17 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Indonesia, Month 12 + 21 Days | 5.98 cells/million T-cells | Standard Deviation 61.91 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Vietnam, Month 12 + 21 Days | 2.44 cells/million T-cells | Standard Deviation 92.98 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Indonesia, Month 18 | 4.22 cells/million T-cells | Standard Deviation 56.87 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Vietnam, Month 18 | 3.84 cells/million T-cells | Standard Deviation 75.59 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Vietnam, Day 0 | 22.25 cells/million T-cells | Standard Deviation 202.4 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Vietnam, Month 6 | 30.85 cells/million T-cells | Standard Deviation 186.03 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Indonesia, Month 12 | 18.29 cells/million T-cells | Standard Deviation 246.48 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Vietnam, Month 12 | 12.06 cells/million T-cells | Standard Deviation 148.06 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Indonesia, Month 12 + 7 Days | 36.88 cells/million T-cells | Standard Deviation 268.94 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Vietnam, Month 12 + 7 Days | 23.40 cells/million T-cells | Standard Deviation 399.09 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Indonesia, Month 12 + 21 Days | 19.97 cells/million T-cells | Standard Deviation 198.1 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Vietnam, Month 12 + 21 Days | 8.59 cells/million T-cells | Standard Deviation 207.18 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Indonesia, Month 18 | 31.29 cells/million T-cells | Standard Deviation 340.1 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Vietnam, Month 18 | 15.08 cells/million T-cells | Standard Deviation 211.25 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Vietnam, Day 0 | 22.01 cells/million T-cells | Standard Deviation 312.45 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Vietnam, Month 6 | 42.77 cells/million T-cells | Standard Deviation 334.23 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Indonesia, Month 12 | 6.58 cells/million T-cells | Standard Deviation 85.93 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Vietnam, Month 12 | 7.07 cells/million T-cells | Standard Deviation 174.18 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Indonesia, Month 12 + 7 Days | 15.65 cells/million T-cells | Standard Deviation 111.26 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Vietnam, Month 12 + 7 Days | 7.45 cells/million T-cells | Standard Deviation 181.01 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Indonesia, Month 12 + 21 Days | 7.48 cells/million T-cells | Standard Deviation 123.95 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Vietnam, Month 12 + 21 Days | 6.84 cells/million T-cells | Standard Deviation 235.75 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Indonesia, Month 18 | 12.19 cells/million T-cells | Standard Deviation 79.29 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Vietnam, Month 18 | 9.36 cells/million T-cells | Standard Deviation 182.9 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Vietnam, Day 0 | 19.36 cells/million T-cells | Standard Deviation 258.56 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Vietnam, Month 6 | 25.01 cells/million T-cells | Standard Deviation 272.87 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Indonesia, Month 12 | 15.38 cells/million T-cells | Standard Deviation 263.83 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Vietnam, Month 12 | 11.32 cells/million T-cells | Standard Deviation 106.95 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Indonesia, Month 12 + 7 Days | 34.22 cells/million T-cells | Standard Deviation 261.37 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Vietnam, Month 12 + 7 Days | 17.27 cells/million T-cells | Standard Deviation 340.5 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Indonesia, Month 12 + 21 Days | 23.41 cells/million T-cells | Standard Deviation 155.91 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Vietnam, Month 12 + 21 Days | 10.85 cells/million T-cells | Standard Deviation 228.98 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Indonesia, Month 18 | 24.97 cells/million T-cells | Standard Deviation 337.4 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Vietnam, Month 18 | 14.16 cells/million T-cells | Standard Deviation 217.05 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Vietnam, Day 0 | 529.20 cells/million T-cells | Standard Deviation 549.34 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Vietnam, Month 6 | 931.49 cells/million T-cells | Standard Deviation 717.72 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Indonesia, Month 12 | 1254.05 cells/million T-cells | Standard Deviation 835.74 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Vietnam, Month 12 | 1093.54 cells/million T-cells | Standard Deviation 941.19 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Indonesia, Month 12 + 7 Days | 1763.05 cells/million T-cells | Standard Deviation 1266.55 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Vietnam, Month 12 + 7 days | 1856.17 cells/million T-cells | Standard Deviation 1517.33 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Indonesia, Month 12 + 21 Days | 2180.14 cells/million T-cells | Standard Deviation 2032.36 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Vietnam, Month 12 + 21 Days | 2276.18 cells/million T-cells | Standard Deviation 1434.51 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Indonesia, Month 18 | 1530.61 cells/million T-cells | Standard Deviation 1228.44 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Vietnam, Month 18 | 1628.90 cells/million T-cells | Standard Deviation 2059.72 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Vietnam, Day 0 | 505.20 cells/million T-cells | Standard Deviation 497.95 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Vietnam, Month 6 | 891.65 cells/million T-cells | Standard Deviation 657.93 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Indonesia, Month 12 | 1209.07 cells/million T-cells | Standard Deviation 715.01 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Vietnam, Month 12 | 1059.77 cells/million T-cells | Standard Deviation 917.49 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Indonesia, Month 12 + 7 Days | 1724.77 cells/million T-cells | Standard Deviation 1242.19 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Vietnam, Month 12 + 7 Days | 1781.72 cells/million T-cells | Standard Deviation 1287.53 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Indonesia, Month 12 + 21 Days | 2097.74 cells/million T-cells | Standard Deviation 1860.85 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Vietnam, Month 12 + 21 Days | 2184.58 cells/million T-cells | Standard Deviation 1371.47 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Indonesia, Month 18 | 1532.05 cells/million T-cells | Standard Deviation 1186.69 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Vietnam, Month 18 | 1755.83 cells/million T-cells | Standard Deviation 1930.06 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Vietnam, Day 0 | 409.33 cells/million T-cells | Standard Deviation 480.49 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Vietnam, Month 6 | 804.03 cells/million T-cells | Standard Deviation 632.15 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Indonesia, Month 12 | 1065.33 cells/million T-cells | Standard Deviation 661.19 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Vietnam, Month 12 | 814.08 cells/million T-cells | Standard Deviation 714.13 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Indonesia, Month 12 + 7 Days | 1476.33 cells/million T-cells | Standard Deviation 1015.37 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Vietnam, Month 12 + 7 Days | 1533.21 cells/million T-cells | Standard Deviation 1397.88 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Indonesia, Month 12 + 21 Days | 1858.04 cells/million T-cells | Standard Deviation 1721.69 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Vietnam, Month 12 + 21 Days | 1932.19 cells/million T-cells | Standard Deviation 1276.22 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Indonesia, Month 18 | 1383.29 cells/million T-cells | Standard Deviation 1077.39 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Vietnam, Month 18 | 1394.95 cells/million T-cells | Standard Deviation 1933.81 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Vietnam, Day 0 | 336.74 cells/million T-cells | Standard Deviation 443.2 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Vietnam, Month 6 | 539.79 cells/million T-cells | Standard Deviation 432.94 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Indonesia, Month 12 | 609.84 cells/million T-cells | Standard Deviation 578.82 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Vietnam, Month 12 | 565.44 cells/million T-cells | Standard Deviation 574.28 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Indonesia, Month 12 + 7 Days | 812.11 cells/million T-cells | Standard Deviation 693.8 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Vietnam, Month 12 + 7 Days | 892.51 cells/million T-cells | Standard Deviation 905.48 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Indonesia, Month 12 + 21 Days | 948.13 cells/million T-cells | Standard Deviation 1366.34 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Vietnam, Month 12 + 21 Days | 1074.61 cells/million T-cells | Standard Deviation 717.53 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Indonesia, Month 18 | 902.31 cells/million T-cells | Standard Deviation 742.69 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Vietnam, Month 18 | 901.99 cells/million T-cells | Standard Deviation 1416.15 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Vietnam, Day 0 | 287.10 cells/million T-cells | Standard Deviation 423.56 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Vietnam, Month 6 | 629.87 cells/million T-cells | Standard Deviation 556.2 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Indonesia, Month 12 | 896.53 cells/million T-cells | Standard Deviation 690.42 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Vietnam, Month 12 | 673.80 cells/million T-cells | Standard Deviation 651.52 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Indonesia, Month 12 + 7 Days | 1217.50 cells/million T-cells | Standard Deviation 971.57 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Vietnam, Month 12 + 7 Days | 1136.90 cells/million T-cells | Standard Deviation 1164.93 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Indonesia, Month 12 + 21 Days | 1515.97 cells/million T-cells | Standard Deviation 1751.14 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Indonesia, Month 12 + 7 Days | 10.25 cells/million T-cells | Standard Deviation 163.04 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Vietnam, Month 12 + 21 Days | 8.45 cells/million T-cells | Standard Deviation 210.82 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Vietnam, Month 12 | 8.90 cells/million T-cells | Standard Deviation 107.93 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Indonesia, Month 18 | 27.31 cells/million T-cells | Standard Deviation 164.07 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Vietnam, Month 6 | 16.53 cells/million T-cells | Standard Deviation 173.9 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Indonesia, Month 12 + 21 Days | 2800.66 cells/million T-cells | Standard Deviation 2480.69 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Vietnam, Month 18 | 16.70 cells/million T-cells | Standard Deviation 368.21 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Vietnam, Month 12 + 7 Days | 1335.77 cells/million T-cells | Standard Deviation 1104.69 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Vietnam, Day 0 | 542.86 cells/million T-cells | Standard Deviation 488.28 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Vietnam, Day 0 | 10.40 cells/million T-cells | Standard Deviation 167 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Vietnam, Month 6 | 1714.23 cells/million T-cells | Standard Deviation 837.39 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Indonesia, Month 12 | 1690.38 cells/million T-cells | Standard Deviation 1135.04 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Vietnam, Month 18 | 4.78 cells/million T-cells | Standard Deviation 62.03 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Indonesia, Month 12 + 7 Days | 2108.88 cells/million T-cells | Standard Deviation 1380.62 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Vietnam, Month 12 | 1260.93 cells/million T-cells | Standard Deviation 1118.44 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Indonesia, Month 12 + 21 Days | 1540.77 cells/million T-cells | Standard Deviation 1136.61 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Indonesia, Month 12 + 7 Days | 3030.85 cells/million T-cells | Standard Deviation 1974.08 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Indonesia, Month 18 | 2.45 cells/million T-cells | Standard Deviation 37.14 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Vietnam, Month 12 + 7 days | 2953.57 cells/million T-cells | Standard Deviation 2725.45 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Indonesia, Month 12 | 33.27 cells/million T-cells | Standard Deviation 237.99 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Indonesia, Month 12 + 21 Days | 3600.62 cells/million T-cells | Standard Deviation 2903.9 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Vietnam, Month 12 + 21 Days | 3.11 cells/million T-cells | Standard Deviation 32.25 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Vietnam, Month 12 + 21 Days | 3386.98 cells/million T-cells | Standard Deviation 3153.08 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Vietnam, Month 12 + 21 Days | 1539.76 cells/million T-cells | Standard Deviation 1287.82 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Indonesia, Month 18 | 2975.66 cells/million T-cells | Standard Deviation 1696.72 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Indonesia, Month 12 + 21 Days | 8.29 cells/million T-cells | Standard Deviation 57.18 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Vietnam, Month 18 | 2972.79 cells/million T-cells | Standard Deviation 1797.59 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Vietnam, Day 0 | 504.23 cells/million T-cells | Standard Deviation 476.25 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Vietnam, Month 12 + 7 Days | 2.90 cells/million T-cells | Standard Deviation 39.63 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Indonesia, Month 18 | 2445.88 cells/million T-cells | Standard Deviation 1505.1 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Vietnam, Month 6 | 1659.46 cells/million T-cells | Standard Deviation 823.79 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Indonesia, Month 18 | 1329.00 cells/million T-cells | Standard Deviation 814.58 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Indonesia, Month 12 | 1610.40 cells/million T-cells | Standard Deviation 1079.91 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Indonesia, Month 12 + 7 Days | 13.23 cells/million T-cells | Standard Deviation 99.16 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Vietnam, Month 12 | 1217.48 cells/million T-cells | Standard Deviation 1056.53 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Vietnam, Month 6 | 31.83 cells/million T-cells | Standard Deviation 296.96 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Indonesia, Month 12 + 7 Days | 2880.43 cells/million T-cells | Standard Deviation 1936.74 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Vietnam, Month 12 | 2.16 cells/million T-cells | Standard Deviation 52.15 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Vietnam, Month 12 + 7 Days | 2842.20 cells/million T-cells | Standard Deviation 2607.8 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Vietnam, Month 18 | 1418.76 cells/million T-cells | Standard Deviation 1038.94 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Indonesia, Month 12 + 21 Days | 3431.78 cells/million T-cells | Standard Deviation 2897.09 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Indonesia, Month 12 | 4.44 cells/million T-cells | Standard Deviation 40.48 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Vietnam, Month 12 + 21 Days | 3179.78 cells/million T-cells | Standard Deviation 3132.51 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Indonesia, Month 18 | 2859.97 cells/million T-cells | Standard Deviation 1657.11 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Vietnam, Month 6 | 3.00 cells/million T-cells | Standard Deviation 101.52 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Vietnam, Month 12 + 7 Days | 1997.48 cells/million T-cells | Standard Deviation 1725.2 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Vietnam, Month 18 | 2849.08 cells/million T-cells | Standard Deviation 1755.65 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Vietnam, Day 0 | 341.11 cells/million T-cells | Standard Deviation 356.99 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Vietnam, Day 0 | 436.65 cells/million T-cells | Standard Deviation 411.16 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Vietnam, Day 0 | 2.48 cells/million T-cells | Standard Deviation 130.89 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Vietnam, Month 6 | 1461.85 cells/million T-cells | Standard Deviation 769.17 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Vietnam, Day 0 | 18.67 cells/million T-cells | Standard Deviation 297.54 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Indonesia, Month 12 | 1517.94 cells/million T-cells | Standard Deviation 1028.9 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Vietnam, Month 18 | 26.49 cells/million T-cells | Standard Deviation 396.9 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Vietnam, Month 12 | 1083.65 cells/million T-cells | Standard Deviation 1008.19 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Vietnam, Month 6 | 1187.24 cells/million T-cells | Standard Deviation 710.18 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Indonesia, Month 12 + 7 Days | 2543.33 cells/million T-cells | Standard Deviation 1712.8 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Indonesia, Month 18 | 29.12 cells/million T-cells | Standard Deviation 194.72 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Vietnam, Month 12 + 7 Days | 2477.58 cells/million T-cells | Standard Deviation 2347.38 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Indonesia, Month 12 + 21 Days | 3108.60 cells/million T-cells | Standard Deviation 2632.6 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Vietnam, Month 12 + 21 Days | 16.58 cells/million T-cells | Standard Deviation 227.02 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Vietnam, Month 12 + 21 Days | 2992.35 cells/million T-cells | Standard Deviation 2869.19 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Indonesia, Month 12 | 1251.38 cells/million T-cells | Standard Deviation 970.03 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Indonesia, Month 18 | 2559.41 cells/million T-cells | Standard Deviation 1683.14 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Indonesia, Month 12 + 21 Days | 42.28 cells/million T-cells | Standard Deviation 213.86 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Vietnam, Month 18 | 2589.97 cells/million T-cells | Standard Deviation 1776.18 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Vietnam, Month 18 | 2269.35 cells/million T-cells | Standard Deviation 1494.81 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Vietnam, Day 0 | 379.98 cells/million T-cells | Standard Deviation 364.14 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Vietnam, Day 0 | 16.63 cells/million T-cells | Standard Deviation 273.01 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Vietnam, Month 6 | 24.28 cells/million T-cells | Standard Deviation 290.45 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Vietnam, Month 12 + 7 Days | 9.04 cells/million T-cells | Standard Deviation 325.93 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Indonesia, Month 12 | 19.40 cells/million T-cells | Standard Deviation 172.59 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Vietnam, Month 18 | 14.48 cells/million T-cells | Standard Deviation 250.77 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Vietnam, Month 12 + 21 Days | 2373.80 cells/million T-cells | Standard Deviation 2542.38 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Vietnam, Month 12 | 4.31 cells/million T-cells | Standard Deviation 101.18 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Vietnam, Month 6 | 771.40 cells/million T-cells | Standard Deviation 459.71 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Indonesia, Month 18 | 19.06 cells/million T-cells | Standard Deviation 157.42 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Vietnam, Month 12 + 7 Days | 7.59 cells/million T-cells | Standard Deviation 236.89 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Indonesia, Month 12 + 21 Days | 6.66 cells/million T-cells | Standard Deviation 65.2 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Vietnam, Month 12 + 21 Days | 14.20 cells/million T-cells | Standard Deviation 208.85 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Vietnam, Month 12 | 790.01 cells/million T-cells | Standard Deviation 938.28 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Vietnam, Month 12 + 21 Days | 6.18 cells/million T-cells | Standard Deviation 111.67 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Indonesia, Month 12 | 832.27 cells/million T-cells | Standard Deviation 746.45 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Indonesia, Month 18 | 7.77 cells/million T-cells | Standard Deviation 113.83 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Indonesia, Month 12 + 21 Days | 31.51 cells/million T-cells | Standard Deviation 216.34 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Vietnam, Month 18 | 5.10 cells/million T-cells | Standard Deviation 351.48 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Indonesia, Month 12 + 7 Days | 41.66 cells/million T-cells | Standard Deviation 276.01 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Vietnam, Day 0 | 11.36 cells/million T-cells | Standard Deviation 179.18 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Vietnam, Month 12 + 7 Days | 8.29 cells/million T-cells | Standard Deviation 278.07 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Vietnam, Month 6 | 26.33 cells/million T-cells | Standard Deviation 205.26 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Vietnam, Month 12 | 633.07 cells/million T-cells | Standard Deviation 650.52 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Indonesia, Month 12 | 24.41 cells/million T-cells | Standard Deviation 194.37 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Indonesia, Month 12 + 7 Days | 28.07 cells/million T-cells | Standard Deviation 261.31 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Vietnam, Month 12 | 6.46 cells/million T-cells | Standard Deviation 81.15 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Indonesia, Month 12 + 7 Days | 35.18 cells/million T-cells | Standard Deviation 233.51 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Vietnam, Month 12 | 8.22 cells/million T-cells | Standard Deviation 80.21 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Vietnam, Month 12 + 7 Days | 8.21 cells/million T-cells | Standard Deviation 300.02 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Indonesia, Month 12 + 7 Days | 1308.07 cells/million T-cells | Standard Deviation 966.01 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Indonesia, Month 12 + 21 Days | 31.57 cells/million T-cells | Standard Deviation 210.43 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Indonesia, Month 12 | 17.80 cells/million T-cells | Standard Deviation 236.04 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Vietnam, Month 12 | 903.64 cells/million T-cells | Standard Deviation 2220.85 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Vietnam, Month 6 | 748.72 cells/million T-cells | Standard Deviation 758.34 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Vietnam, Month 12 + 21 Days | 35.54 cells/million T-cells | Standard Deviation 288.39 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Vietnam, Month 6 | 19.63 cells/million T-cells | Standard Deviation 145.48 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Indonesia, Month 12 | 1293.00 cells/million T-cells | Standard Deviation 1103.73 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Vietnam, Month 12 + 7 Days | 44.13 cells/million T-cells | Standard Deviation 394.01 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Indonesia, Month 18 | 31.10 cells/million T-cells | Standard Deviation 361.58 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Vietnam, Month 12 + 7 Days | 2466.32 cells/million T-cells | Standard Deviation 16740.25 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Vietnam, Month 12 + 7 Days | 41.24 cells/million T-cells | Standard Deviation 348.65 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Vietnam, Month 12 | 1048.97 cells/million T-cells | Standard Deviation 2636.29 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Vietnam, Month 18 | 18.60 cells/million T-cells | Standard Deviation 170.85 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Vietnam, Day 0 | 15.03 cells/million T-cells | Standard Deviation 86.58 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Indonesia, Month 18 | 36.73 cells/million T-cells | Standard Deviation 391.36 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Vietnam, Month 12 + 21 Days | 47.66 cells/million T-cells | Standard Deviation 280.88 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Vietnam, Day 0 | 771.60 cells/million T-cells | Standard Deviation 788.54 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Indonesia, Month 12 + 7 Days | 57.43 cells/million T-cells | Standard Deviation 369.42 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Vietnam, Month 12 + 7 Days | 1635.21 cells/million T-cells | Standard Deviation 7167.21 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Indonesia, Month 12 + 7 Days | 2670.96 cells/million T-cells | Standard Deviation 5571.66 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Vietnam, Month 6 | 1601.31 cells/million T-cells | Standard Deviation 1020.97 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Vietnam, Month 18 | 2.09 cells/million T-cells | Standard Deviation 59.01 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Indonesia, Month 12 | 34.16 cells/million T-cells | Standard Deviation 449.53 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Vietnam, Month 6 | 30.46 cells/million T-cells | Standard Deviation 172.62 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Indonesia, Month 12 | 1534.37 cells/million T-cells | Standard Deviation 1256.2 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Vietnam, Month 6 | 1180.29 cells/million T-cells | Standard Deviation 829.76 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Indonesia, Month 12 + 21 Days | 13.34 cells/million T-cells | Standard Deviation 135.85 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Vietnam, Month 12 + 7 Days | 2942.81 cells/million T-cells | Standard Deviation 17299.39 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Vietnam, Month 12 | 1224.35 cells/million T-cells | Standard Deviation 2953.68 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Indonesia, Month 18 | 2.75 cells/million T-cells | Standard Deviation 36.15 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Vietnam, Month 12 + 21 Days | 51.01 cells/million T-cells | Standard Deviation 320.71 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Vietnam, Month 18 | 1914.16 cells/million T-cells | Standard Deviation 2270.93 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Indonesia, Month 12 + 7 Days | 3202.67 cells/million T-cells | Standard Deviation 7114.42 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Indonesia, Month 12 + 7 Days | 61.72 cells/million T-cells | Standard Deviation 318.59 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Indonesia, Month 12 + 21 Days | 1662.38 cells/million T-cells | Standard Deviation 1310.77 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Indonesia, Month 12 + 21 Days | 2747.73 cells/million T-cells | Standard Deviation 2516.72 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Vietnam, Month 12 + 7 days | 3502.70 cells/million T-cells | Standard Deviation 19908.39 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Vietnam, Month 12 + 21 Days | 3.70 cells/million T-cells | Standard Deviation 34.54 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Indonesia, Month 12 + 7 Days | 32.53 cells/million T-cells | Standard Deviation 309.18 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Vietnam, Month 12 + 21 Days | 2571.60 cells/million T-cells | Standard Deviation 3441.06 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Indonesia, Month 12 + 21 Days | 3221.46 cells/million T-cells | Standard Deviation 2824.65 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Indonesia, Month 12 | 28.56 cells/million T-cells | Standard Deviation 430.21 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Indonesia, Month 12 + 7 Days | 2379.07 cells/million T-cells | Standard Deviation 5801.63 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Vietnam, Month 12 + 21 Days | 3105.21 cells/million T-cells | Standard Deviation 3366.65 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Vietnam, Month 12 + 21 Days | 3603.01 cells/million T-cells | Standard Deviation 3804.83 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Indonesia, Month 12 + 21 Days | 7.45 cells/million T-cells | Standard Deviation 96.27 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Indonesia, Month 12 + 21 Days | 60.95 cells/million T-cells | Standard Deviation 301.71 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Vietnam, Month 12 + 21 Days | 15.18 cells/million T-cells | Standard Deviation 269.18 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Indonesia, Month 18 | 2458.61 cells/million T-cells | Standard Deviation 1829.69 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Indonesia, Month 12 + 21 Days | 43.10 cells/million T-cells | Standard Deviation 277.22 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Vietnam, Month 12 + 21 Days | 1795.04 cells/million T-cells | Standard Deviation 2122.78 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Indonesia, Month 18 | 2104.29 cells/million T-cells | Standard Deviation 1607.98 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 All Doubles - A/Vietnam, Month 18 | 2535.97 cells/million T-cells | Standard Deviation 2627.53 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Vietnam, Month 12 + 7 Days | 10.59 cells/million T-cells | Standard Deviation 52.19 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Vietnam, Month 6 | 34.66 cells/million T-cells | Standard Deviation 208.62 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Indonesia, Month 12 | 25.59 cells/million T-cells | Standard Deviation 330.65 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Vietnam, Day 0 | 729.16 cells/million T-cells | Standard Deviation 736.68 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Indonesia, Month 12 | 995.80 cells/million T-cells | Standard Deviation 1066.3 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Indonesia, Month 18 | 1979.21 cells/million T-cells | Standard Deviation 1590.6 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Vietnam, Month 18 | 2162.08 cells/million T-cells | Standard Deviation 2461.02 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Vietnam, Month 6 | 1548.04 cells/million T-cells | Standard Deviation 918.09 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Indonesia, Month 12 + 7 Days | 7.76 cells/million T-cells | Standard Deviation 99.48 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Vietnam, Month 12 + 7 Days | 62.81 cells/million T-cells | Standard Deviation 426.34 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Indonesia, Month 18 | 6.53 cells/million T-cells | Standard Deviation 164.84 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Indonesia, Month 12 | 1478.55 cells/million T-cells | Standard Deviation 1259.28 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Vietnam, Month 12 | 767.14 cells/million T-cells | Standard Deviation 1198.67 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Indonesia, Month 18 | 1292.88 cells/million T-cells | Standard Deviation 1081.31 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Vietnam, Day 0 | 24.90 cells/million T-cells | Standard Deviation 165.67 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Vietnam, Month 12 | 1173.39 cells/million T-cells | Standard Deviation 2904.15 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Vietnam, Month 12 | 2.87 cells/million T-cells | Standard Deviation 40.66 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Indonesia, Month 12 | 794.44 cells/million T-cells | Standard Deviation 765.51 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Vietnam, Day 0 | 476.66 cells/million T-cells | Standard Deviation 687.6 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Indonesia, Month 12 + 7 Days | 3101.88 cells/million T-cells | Standard Deviation 6940.95 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Indonesia, Month 12 + 21 Days | 45.94 cells/million T-cells | Standard Deviation 281.82 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Indonesia, Month 12 + 21 Days | 2510.61 cells/million T-cells | Standard Deviation 2450.88 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Vietnam, Month 6 | 30.08 cells/million T-cells | Standard Deviation 200.12 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Vietnam, Month 12 + 7 Days | 3365.20 cells/million T-cells | Standard Deviation 18999.95 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Indonesia, Month 12 | 4.48 cells/million T-cells | Standard Deviation 83.08 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Vietnam, Month 18 | 21.78 cells/million T-cells | Standard Deviation 153.8 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Vietnam, Month 18 | 7.33 cells/million T-cells | Standard Deviation 135.83 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Indonesia, Month 12 + 21 Days | 3124.45 cells/million T-cells | Standard Deviation 2787.9 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Vietnam, Month 12 + 7 Days | 52.32 cells/million T-cells | Standard Deviation 392.4 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Vietnam, Month 18 | 1284.53 cells/million T-cells | Standard Deviation 1281.98 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Indonesia, Month 12 | 13.70 cells/million T-cells | Standard Deviation 342.47 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Vietnam, Month 12 + 21 Days | 3479.95 cells/million T-cells | Standard Deviation 3622.29 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Vietnam, Month 6 | 1.51 cells/million T-cells | Standard Deviation 20.14 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Vietnam, Day 0 | 21.71 cells/million T-cells | Standard Deviation 163.41 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Vietnam, Month 12 | 19.46 cells/million T-cells | Standard Deviation 337.02 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Indonesia, Month 18 | 2317.11 cells/million T-cells | Standard Deviation 1865.51 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Vietnam, Month 12 | 35.92 cells/million T-cells | Standard Deviation 362.09 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 TNF-α - A/Vietnam, Day 0 | 14.50 cells/million T-cells | Standard Deviation 136.3 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Vietnam, Month 12 | 9.04 cells/million T-cells | Standard Deviation 120.34 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 CD40L - A/Vietnam, Month 18 | 2483.47 cells/million T-cells | Standard Deviation 2583.46 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 CD40L - A/Vietnam, Day 0 | 2.79 cells/million T-cells | Standard Deviation 19.72 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IL-2 - A/Indonesia, Month 18 | 31.56 cells/million T-cells | Standard Deviation 385.23 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Vietnam, Month 12 | 30.14 cells/million T-cells | Standard Deviation 365.9 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Vietnam, Day 0 | 612.11 cells/million T-cells | Standard Deviation 632.55 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IFN-γ - A/Indonesia, Month 12 + 7 Days | 1560.86 cells/million T-cells | Standard Deviation 2907.99 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 TNF-α - A/Vietnam, Day 0 | 512.64 cells/million T-cells | Standard Deviation 572.95 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 IFN-γ - A/Indonesia, Month 12 + 7 Days | 18.89 cells/million T-cells | Standard Deviation 170.88 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD4 IL-2 - A/Vietnam, Month 6 | 1403.84 cells/million T-cells | Standard Deviation 915.32 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 | CD8 All Doubles - A/Vietnam, Month 18 | 17.79 cells/million T-cells | Standard Deviation 189.35 |
Secondary
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6
Among cytokines expressed after background reduction were cluster of differentiation 4 all doubles (CD4 All Doubles), cluster of differentiation 40-ligand (CD40-L), interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α). The 2 flu strains assessed were A/Indonesia/05/2005 and A/Vietnam/1194/2004.
Time frame: At Day 0, Month 6, Month 6 + 7 Days, Month 6 + 21 Days, Month 12 and Month 18
Population: This analysis was performed on the ATP Cohort for Immunogenicity and ATP Cohort for Persistence (only for M12, M18), which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IL-2 - A/Vietnam, Month 18 | 32.16 cells/million T-cells | Standard Deviation 615.73 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IFN-γ - A/Vietnam, Month 6 | 309.94 cells/million T-cells | Standard Deviation 596.66 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IFN-γ - A/Vietnam, Day 0 | 303.97 cells/million T-cells | Standard Deviation 403.9 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 All Doubles - A/Indonesia, Month 18 | 1192.82 cells/million T-cells | Standard Deviation 1000.13 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 CD40L - A/Vietnam, Month 18 | 5.71 cells/million T-cells | Standard Deviation 53.55 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IL-2- A/Vietnam, Month 18 | 1011.14 cells/million T-cells | Standard Deviation 921.27 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IL-2 - A/Indonesia, Month 18 | 999.22 cells/million T-cells | Standard Deviation 844.48 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 All Doubles - A/Vietnam, Month 18 | 1194.69 cells/million T-cells | Standard Deviation 1073.65 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 CD40L - A/Indonesia, Month 18 | 5.88 cells/million T-cells | Standard Deviation 71.14 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IL-2 - A/Vietnam, Month 12 | 1119.56 cells/million T-cells | Standard Deviation 1261.18 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IL-2 - A/Indonesia, Month 12 | 1001.88 cells/million T-cells | Standard Deviation 1156.16 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 CD40L - A/Vietnam, Day 0 | 350.86 cells/million T-cells | Standard Deviation 455.52 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IFN-γ - A/Vietnam, Month 18 | 5.73 cells/million T-cells | Standard Deviation 64.14 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IL-2 - A/Vietnam, Month 6 + 21 Days | 1238.06 cells/million T-cells | Standard Deviation 1759.16 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IL-2 - A/Vietnam, Month 6 + 7 Days | 861.32 cells/million T-cells | Standard Deviation 1997.52 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 CD40L - A/Vietnam, Month 6 | 593.74 cells/million T-cells | Standard Deviation 885.01 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IL-2 - A/Indonesia, Month 18 | 43.26 cells/million T-cells | Standard Deviation 1110.98 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IL-2 - A/Vietnam, Month 6 | 450.20 cells/million T-cells | Standard Deviation 815.29 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IL-2 - A/Vietnam, Day 0 | 262.64 cells/million T-cells | Standard Deviation 339.55 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 CD40L - A/Vietnam, Month 6 + 7 Days | 1084.46 cells/million T-cells | Standard Deviation 2123.12 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 CD40L - A/Vietnam, Month 12 | 2.27 cells/million T-cells | Standard Deviation 33.81 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 CD40L- A/Vietnam, Month 18 | 1162.79 cells/million T-cells | Standard Deviation 1043.15 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 CD40L - A/Indonesia, Month 18 | 1172.36 cells/million T-cells | Standard Deviation 985.13 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 CD40L - A/Vietnam, Month 6 + 21 Days | 1588.60 cells/million T-cells | Standard Deviation 1855.12 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 CD40L - A/Indonesia, Month 12 | 3.92 cells/million T-cells | Standard Deviation 58.33 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 CD40L - A/Vietnam, Month 12 | 1238.24 cells/million T-cells | Standard Deviation 1362.58 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 CD40L - A/Indonesia, Month 12 | 1183.85 cells/million T-cells | Standard Deviation 1255.59 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 TNF-α - A/Vietnam, Day 0 | 25.46 cells/million T-cells | Standard Deviation 308.45 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IFN-γ - A/Vietnam, Month 6 + 21 Days | 9.86 cells/million T-cells | Standard Deviation 272.26 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 CD40L - A/Vietnam, Month 6 + 21 Days | 2.11 cells/million T-cells | Standard Deviation 22.77 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 CD40L - A/Vietnam, Month 6 + 7 Days | 6.26 cells/million T-cells | Standard Deviation 71.82 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 TNF-α - A/Vietnam, Month 6 | 11.60 cells/million T-cells | Standard Deviation 192.99 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IFN-γ - A/Vietnam, Day 0 | 29.70 cells/million T-cells | Standard Deviation 347.16 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 CD40L - A/Vietnam, Month 6 | 3.12 cells/million T-cells | Standard Deviation 35.61 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 CD40L - A/Vietnam, Day 0 | 7.17 cells/million T-cells | Standard Deviation 84.29 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 TNF-α - A/Vietnam, Month 6 + 7 Days | 17.12 cells/million T-cells | Standard Deviation 200.81 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IL-2 - A/Vietnam, Month 12 | 14.98 cells/million T-cells | Standard Deviation 532.13 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 All Doubles - A/Vietnam, Month 18 | 33.20 cells/million T-cells | Standard Deviation 623.81 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 All Doubles - A/Indonesia, Month 18 | 48.27 cells/million T-cells | Standard Deviation 1109.56 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 TNF-α - A/Vietnam, Month 6 + 21 Days | 28.56 cells/million T-cells | Standard Deviation 229.92 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IL-2 - A/Indonesia, Month 12 | 40.26 cells/million T-cells | Standard Deviation 1211.36 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 All Doubles - A/Vietnam, Month 12 | 15.04 cells/million T-cells | Standard Deviation 544.79 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 All Doubles - A/Indonesia, Month 12 | 47.78 cells/million T-cells | Standard Deviation 1206.89 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 TNF-α - A/Indonesia, Month 12 | 46.49 cells/million T-cells | Standard Deviation 1154.66 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IFN-γ - A/Indonesia, Month 12 | 3.05 cells/million T-cells | Standard Deviation 131.52 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 All Doubles - A/Vietnam, Month 6 + 21 Days | 29.21 cells/million T-cells | Standard Deviation 281.87 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 All Doubles - A/Vietnam, Month 6 + 7 Days | 23.01 cells/million T-cells | Standard Deviation 290.71 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 TNF-α - A/Vietnam, Month 12 | 13.46 cells/million T-cells | Standard Deviation 423.36 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IFN-γ - A/Vietnam, Month 6 + 7 days | 17.52 cells/million T-cells | Standard Deviation 252.3 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 All Doubles - A/Vietnam, Month 6 | 20.86 cells/million T-cells | Standard Deviation 222.56 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 All Doubles - A/Vietnam, Day 0 | 67.13 cells/million T-cells | Standard Deviation 366.43 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 TNF-α - A/Indonesia, Month 18 | 45.67 cells/million T-cells | Standard Deviation 1033.79 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IL-2 - A/Vietnam, Month 6 + 21 Days | 31.00 cells/million T-cells | Standard Deviation 185.96 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 TNF-α - A/Vietnam, Month 18 | 877.90 cells/million T-cells | Standard Deviation 810.8 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 TNF-α - A/Indonesia, Month 18 | 922.42 cells/million T-cells | Standard Deviation 794.83 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 TNF-α - A/Vietnam, Month 18 | 31.41 cells/million T-cells | Standard Deviation 580.62 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IL-2 - A/Vietnam, Month 6 + 7 Days | 16.03 cells/million T-cells | Standard Deviation 218.16 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 TNF-α - A/Vietnam, Month 12 | 970.90 cells/million T-cells | Standard Deviation 1091.23 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 TNF-α - A/Indonesia, Month 12 | 914.94 cells/million T-cells | Standard Deviation 1053.34 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 All Doubles - A/Vietnam, Day 0 | 412.03 cells/million T-cells | Standard Deviation 487.53 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IFN-γ - A/Vietnam, Month 12 | 4.44 cells/million T-cells | Standard Deviation 305.15 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 TNF-α - A/Vietnam, Month 6 + 21 Days | 880.12 cells/million T-cells | Standard Deviation 1327.15 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 TNF-α - A/Vietnam, Month 6 + 7 Days | 605.80 cells/million T-cells | Standard Deviation 1282.37 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 All Doubles - A/Vietnam, Month 6 | 600.07 cells/million T-cells | Standard Deviation 901.78 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IFN-γ - A/Vietnam, Month 6 | 9.15 cells/million T-cells | Standard Deviation 195.76 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 TNF-α - A/Vietnam, Month 6 | 389.55 cells/million T-cells | Standard Deviation 823.34 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 TNF-α - A/Vietnam, Day 0 | 213.17 cells/million T-cells | Standard Deviation 314.89 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 All Doubles - A/Vietnam, Month 6 + 7 Days | 1120.95 cells/million T-cells | Standard Deviation 2182.54 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IL-2 - A/Vietnam, Month 6 | 12.84 cells/million T-cells | Standard Deviation 129.21 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IFN-γ - A/Vietnam, Month 18 | 698.55 cells/million T-cells | Standard Deviation 804.64 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IFN-γ - A/Indonesia, Month 18 | 657.19 cells/million T-cells | Standard Deviation 622.98 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 All Doubles - A/Vietnam, Month 6 + 21 Days | 1619.46 cells/million T-cells | Standard Deviation 1899.48 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IL-2 - A/Vietnam, Day 0 | 36.92 cells/million T-cells | Standard Deviation 229 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IFN-γ - A/Vietnam, Month 12 | 751.16 cells/million T-cells | Standard Deviation 604.7 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IFN-γ - A/Indonesia, Month 12 | 615.47 cells/million T-cells | Standard Deviation 624.58 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 All Doubles - A/Indonesia, Month 12 | 1196.05 cells/million T-cells | Standard Deviation 1279.6 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IFN-γ - A/Indonesia, Month 18 | 4.74 cells/million T-cells | Standard Deviation 91.61 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IFN-γ - A/Vietnam, Month 6 + 21 Days | 769.33 cells/million T-cells | Standard Deviation 858.31 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IFN-γ - A/Vietnam, Month 6 + 7 Days | 632.73 cells/million T-cells | Standard Deviation 848 |
| GSK1562902A V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 All Doubles - A/Vietnam, Month 12 | 1316.68 cells/million T-cells | Standard Deviation 1359.39 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 TNF-α - A/Vietnam, Month 6 + 21 Days | 971.44 cells/million T-cells | Standard Deviation 1419.68 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IFN-γ - A/Vietnam, Month 6 + 7 days | 6.54 cells/million T-cells | Standard Deviation 65.11 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IFN-γ - A/Vietnam, Month 6 + 21 Days | 16.87 cells/million T-cells | Standard Deviation 111.49 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IFN-γ - A/Indonesia, Month 12 | 4.05 cells/million T-cells | Standard Deviation 147.2 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IFN-γ - A/Vietnam, Month 12 | 4.24 cells/million T-cells | Standard Deviation 133.39 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IFN-γ - A/Indonesia, Month 18 | 4.33 cells/million T-cells | Standard Deviation 111.98 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IFN-γ - A/Vietnam, Month 18 | 3.55 cells/million T-cells | Standard Deviation 138.59 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 TNF-α - A/Vietnam, Day 0 | 14.67 cells/million T-cells | Standard Deviation 92.23 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 TNF-α - A/Vietnam, Month 6 | 17.44 cells/million T-cells | Standard Deviation 260.42 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 TNF-α - A/Vietnam, Month 6 + 7 Days | 14.74 cells/million T-cells | Standard Deviation 90.05 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 TNF-α - A/Vietnam, Month 6 + 21 Days | 38.71 cells/million T-cells | Standard Deviation 137.2 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 TNF-α - A/Indonesia, Month 12 | 27.72 cells/million T-cells | Standard Deviation 1030.52 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 TNF-α - A/Vietnam, Month 12 | 18.89 cells/million T-cells | Standard Deviation 579.22 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 TNF-α - A/Indonesia, Month 18 | 22.55 cells/million T-cells | Standard Deviation 1002.19 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 TNF-α - A/Vietnam, Month 18 | 12.96 cells/million T-cells | Standard Deviation 816.63 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 All Doubles - A/Vietnam, Day 0 | 467.30 cells/million T-cells | Standard Deviation 333.87 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 All Doubles - A/Vietnam, Month 6 | 807.14 cells/million T-cells | Standard Deviation 806.63 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 All Doubles - A/Vietnam, Month 6 + 7 Days | 1369.15 cells/million T-cells | Standard Deviation 1224.75 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 All Doubles - A/Vietnam, Month 6 + 21 Days | 1531.69 cells/million T-cells | Standard Deviation 1741.38 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 All Doubles - A/Indonesia, Month 12 | 1461.46 cells/million T-cells | Standard Deviation 1972.69 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 All Doubles - A/Vietnam, Month 12 | 1431.92 cells/million T-cells | Standard Deviation 1291.8 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 All Doubles - A/Indonesia, Month 18 | 1767.82 cells/million T-cells | Standard Deviation 1194.85 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 All Doubles - A/Vietnam, Month 18 | 1790.56 cells/million T-cells | Standard Deviation 1178.39 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 CD40L - A/Vietnam, Day 0 | 446.27 cells/million T-cells | Standard Deviation 318.18 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 CD40L - A/Vietnam, Month 6 | 809.47 cells/million T-cells | Standard Deviation 777.2 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 CD40L - A/Vietnam, Month 6 + 7 Days | 1298.95 cells/million T-cells | Standard Deviation 1153.28 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 CD40L - A/Vietnam, Month 6 + 21 Days | 1487.73 cells/million T-cells | Standard Deviation 1663.98 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 CD40L - A/Indonesia, Month 12 | 1448.44 cells/million T-cells | Standard Deviation 1973.98 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 CD40L - A/Vietnam, Month 12 | 1390.02 cells/million T-cells | Standard Deviation 1288.92 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 CD40L - A/Indonesia, Month 18 | 1747.96 cells/million T-cells | Standard Deviation 1151.98 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 CD40L- A/Vietnam, Month 18 | 1738.30 cells/million T-cells | Standard Deviation 1140.59 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IL-2 - A/Vietnam, Day 0 | 264.51 cells/million T-cells | Standard Deviation 249.4 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IL-2 - A/Vietnam, Month 6 | 601.02 cells/million T-cells | Standard Deviation 736.05 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IL-2 - A/Vietnam, Month 6 + 7 Days | 890.90 cells/million T-cells | Standard Deviation 1030.87 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IL-2 - A/Vietnam, Month 6 + 21 Days | 1036.73 cells/million T-cells | Standard Deviation 1545.3 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IL-2 - A/Indonesia, Month 12 | 1169.25 cells/million T-cells | Standard Deviation 1630.99 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IL-2 - A/Vietnam, Month 12 | 1160.06 cells/million T-cells | Standard Deviation 1049.95 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IL-2 - A/Indonesia, Month 18 | 1412.43 cells/million T-cells | Standard Deviation 986.25 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IL-2- A/Vietnam, Month 18 | 1487.16 cells/million T-cells | Standard Deviation 1006.2 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IFN-γ - A/Vietnam, Day 0 | 267.88 cells/million T-cells | Standard Deviation 316.2 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IFN-γ - A/Vietnam, Month 6 | 486.23 cells/million T-cells | Standard Deviation 524.58 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IFN-γ - A/Vietnam, Month 6 + 7 Days | 683.35 cells/million T-cells | Standard Deviation 702.66 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IFN-γ - A/Vietnam, Month 6 + 21 Days | 831.31 cells/million T-cells | Standard Deviation 964.67 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IFN-γ - A/Indonesia, Month 12 | 829.05 cells/million T-cells | Standard Deviation 903.32 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IFN-γ - A/Vietnam, Month 12 | 851.71 cells/million T-cells | Standard Deviation 727.68 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IFN-γ - A/Indonesia, Month 18 | 972.81 cells/million T-cells | Standard Deviation 1026.12 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IFN-γ - A/Vietnam, Month 18 | 1018.23 cells/million T-cells | Standard Deviation 959.34 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 TNF-α - A/Vietnam, Day 0 | 290.55 cells/million T-cells | Standard Deviation 244.57 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 TNF-α - A/Vietnam, Month 6 | 459.89 cells/million T-cells | Standard Deviation 709.54 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 TNF-α - A/Vietnam, Month 6 + 7 Days | 700.69 cells/million T-cells | Standard Deviation 893.07 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IFN-γ - A/Vietnam, Month 6 | 15.10 cells/million T-cells | Standard Deviation 164.89 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 TNF-α - A/Indonesia, Month 12 | 1125.16 cells/million T-cells | Standard Deviation 1559.54 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 TNF-α - A/Vietnam, Month 12 | 1047.93 cells/million T-cells | Standard Deviation 978.11 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 TNF-α - A/Indonesia, Month 18 | 1318.59 cells/million T-cells | Standard Deviation 923.86 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 TNF-α - A/Vietnam, Month 18 | 1314.99 cells/million T-cells | Standard Deviation 846.99 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 All Doubles - A/Vietnam, Day 0 | 26.91 cells/million T-cells | Standard Deviation 128.98 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 All Doubles - A/Vietnam, Month 6 | 18.86 cells/million T-cells | Standard Deviation 271.65 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 All Doubles - A/Vietnam, Month 6 + 7 Days | 27.73 cells/million T-cells | Standard Deviation 93.8 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 All Doubles - A/Vietnam, Month 6 + 21 Days | 52.59 cells/million T-cells | Standard Deviation 159.49 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 All Doubles - A/Indonesia, Month 12 | 31.69 cells/million T-cells | Standard Deviation 1136.66 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 All Doubles - A/Vietnam, Month 12 | 21.08 cells/million T-cells | Standard Deviation 635.65 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 All Doubles - A/Indonesia, Month 18 | 24.19 cells/million T-cells | Standard Deviation 1162.3 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 All Doubles - A/Vietnam, Month 18 | 12.14 cells/million T-cells | Standard Deviation 907.62 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 CD40L - A/Vietnam, Day 0 | 4.74 cells/million T-cells | Standard Deviation 71.68 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 CD40L - A/Vietnam, Month 6 | 7.18 cells/million T-cells | Standard Deviation 39.67 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 CD40L - A/Vietnam, Month 6 + 7 Days | 3.55 cells/million T-cells | Standard Deviation 30.06 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 CD40L - A/Vietnam, Month 6 + 21 Days | 4.88 cells/million T-cells | Standard Deviation 37.26 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 CD40L - A/Indonesia, Month 12 | 5.74 cells/million T-cells | Standard Deviation 93.3 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 CD40L - A/Vietnam, Month 12 | 3.40 cells/million T-cells | Standard Deviation 67.73 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 CD40L - A/Indonesia, Month 18 | 5.23 cells/million T-cells | Standard Deviation 269.38 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 CD40L - A/Vietnam, Month 18 | 2.75 cells/million T-cells | Standard Deviation 96.74 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IL-2 - A/Vietnam, Day 0 | 14.67 cells/million T-cells | Standard Deviation 100.62 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IL-2 - A/Vietnam, Month 6 | 12.58 cells/million T-cells | Standard Deviation 239.74 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IL-2 - A/Vietnam, Month 6 + 7 Days | 17.04 cells/million T-cells | Standard Deviation 92.98 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IL-2 - A/Vietnam, Month 6 + 21 Days | 28.04 cells/million T-cells | Standard Deviation 156.16 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IL-2 - A/Indonesia, Month 12 | 27.79 cells/million T-cells | Standard Deviation 1135.75 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IL-2 - A/Vietnam, Month 12 | 21.52 cells/million T-cells | Standard Deviation 631.86 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IL-2 - A/Indonesia, Month 18 | 19.50 cells/million T-cells | Standard Deviation 1164.4 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IL-2 - A/Vietnam, Month 18 | 11.75 cells/million T-cells | Standard Deviation 902.78 |
| GSK1562902A V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IFN-γ - A/Vietnam, Day 0 | 14.50 cells/million T-cells | Standard Deviation 125.14 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 CD40L - A/Vietnam, Month 6 + 7 Days | 1818.39 cells/million T-cells | Standard Deviation 1603.64 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IFN-γ - A/Vietnam, Month 6 | 406.50 cells/million T-cells | Standard Deviation 364.57 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 CD40L - A/Vietnam, Month 18 | 4.14 cells/million T-cells | Standard Deviation 95.17 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IFN-γ - A/Vietnam, Month 6 + 7 Days | 826.27 cells/million T-cells | Standard Deviation 856.63 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 All Doubles - A/Indonesia, Month 12 | 1512.82 cells/million T-cells | Standard Deviation 996.79 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IFN-γ - A/Vietnam, Month 6 + 21 Days | 712.10 cells/million T-cells | Standard Deviation 806.47 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IFN-γ - A/Indonesia, Month 12 | 752.50 cells/million T-cells | Standard Deviation 525.81 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 All Doubles - A/Vietnam, Month 6 + 21 Days | 1489.30 cells/million T-cells | Standard Deviation 1564.28 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IFN-γ - A/Vietnam, Month 6 + 7 days | 6.15 cells/million T-cells | Standard Deviation 190.69 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IFN-γ - A/Vietnam, Month 12 | 817.48 cells/million T-cells | Standard Deviation 568.54 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IL-2 - A/Vietnam, Day 0 | 16.98 cells/million T-cells | Standard Deviation 130.69 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IFN-γ - A/Indonesia, Month 18 | 1017.82 cells/million T-cells | Standard Deviation 655.54 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 All Doubles - A/Vietnam, Month 6 + 7 Days | 1914.50 cells/million T-cells | Standard Deviation 1757.9 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IFN-γ - A/Vietnam, Month 18 | 1066.89 cells/million T-cells | Standard Deviation 845.76 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IFN-γ - A/Vietnam, Month 12 | 10.21 cells/million T-cells | Standard Deviation 83.42 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 TNF-α - A/Vietnam, Day 0 | 248.53 cells/million T-cells | Standard Deviation 334.4 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 All Doubles - A/Vietnam, Month 6 | 896.67 cells/million T-cells | Standard Deviation 627.38 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 TNF-α - A/Vietnam, Month 6 | 501.89 cells/million T-cells | Standard Deviation 496.82 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IL-2 - A/Vietnam, Month 6 | 22.68 cells/million T-cells | Standard Deviation 113.81 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 TNF-α - A/Vietnam, Month 6 + 7 Days | 1160.60 cells/million T-cells | Standard Deviation 1524.45 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 All Doubles - A/Vietnam, Day 0 | 395.60 cells/million T-cells | Standard Deviation 477.64 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 TNF-α - A/Vietnam, Month 6 + 21 Days | 881.65 cells/million T-cells | Standard Deviation 1218.69 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 TNF-α - A/Indonesia, Month 12 | 1235.28 cells/million T-cells | Standard Deviation 813.44 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 TNF-α - A/Vietnam, Month 18 | 21.36 cells/million T-cells | Standard Deviation 614.44 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IL-2 - A/Vietnam, Month 18 | 26.63 cells/million T-cells | Standard Deviation 674.63 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 TNF-α - A/Vietnam, Month 12 | 1238.05 cells/million T-cells | Standard Deviation 858.4 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IL-2 - A/Vietnam, Month 6 + 7 Days | 32.94 cells/million T-cells | Standard Deviation 154.53 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 TNF-α - A/Indonesia, Month 18 | 1647.61 cells/million T-cells | Standard Deviation 927.11 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 TNF-α - A/Indonesia, Month 18 | 70.09 cells/million T-cells | Standard Deviation 1200.29 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 TNF-α - A/Vietnam, Month 18 | 1232.41 cells/million T-cells | Standard Deviation 1079.43 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IFN-γ - A/Indonesia, Month 12 | 4.11 cells/million T-cells | Standard Deviation 75.97 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 All Doubles - A/Vietnam, Day 0 | 30.44 cells/million T-cells | Standard Deviation 219.02 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 TNF-α - A/Vietnam, Month 12 | 35.19 cells/million T-cells | Standard Deviation 698.32 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 All Doubles - A/Vietnam, Month 6 | 37.69 cells/million T-cells | Standard Deviation 271.61 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IL-2 - A/Vietnam, Month 6 + 21 Days | 22.75 cells/million T-cells | Standard Deviation 138.13 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 All Doubles - A/Vietnam, Month 6 + 7 Days | 38.78 cells/million T-cells | Standard Deviation 211.71 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 TNF-α - A/Indonesia, Month 12 | 57.62 cells/million T-cells | Standard Deviation 1753.76 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 All Doubles - A/Vietnam, Month 6 + 21 Days | 36.47 cells/million T-cells | Standard Deviation 171.22 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 All Doubles - A/Indonesia, Month 12 | 64.08 cells/million T-cells | Standard Deviation 1893.94 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 TNF-α - A/Vietnam, Month 6 + 21 Days | 27.86 cells/million T-cells | Standard Deviation 156.35 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 All Doubles - A/Vietnam, Month 12 | 37.32 cells/million T-cells | Standard Deviation 744.75 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IL-2 - A/Indonesia, Month 12 | 48.91 cells/million T-cells | Standard Deviation 1897.48 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 All Doubles - A/Indonesia, Month 18 | 82.90 cells/million T-cells | Standard Deviation 1266.82 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 TNF-α - A/Vietnam, Month 6 + 7 Days | 25.85 cells/million T-cells | Standard Deviation 186.72 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 All Doubles - A/Vietnam, Month 18 | 29.83 cells/million T-cells | Standard Deviation 673.8 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IFN-γ - A/Vietnam, Month 6 + 21 Days | 15.44 cells/million T-cells | Standard Deviation 132.81 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 CD40L - A/Vietnam, Day 0 | 5.49 cells/million T-cells | Standard Deviation 39.03 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 TNF-α - A/Vietnam, Month 6 | 21.86 cells/million T-cells | Standard Deviation 254.39 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IFN-γ - A/Vietnam, Month 6 | 25.09 cells/million T-cells | Standard Deviation 269.6 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 CD40L - A/Vietnam, Month 6 | 5.01 cells/million T-cells | Standard Deviation 69.22 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IL-2 - A/Vietnam, Month 12 | 31.94 cells/million T-cells | Standard Deviation 746.85 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 CD40L - A/Vietnam, Month 6 + 7 Days | 6.28 cells/million T-cells | Standard Deviation 34.99 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 TNF-α - A/Vietnam, Day 0 | 22.21 cells/million T-cells | Standard Deviation 183.41 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 CD40L - A/Vietnam, Month 6 + 21 Days | 3.78 cells/million T-cells | Standard Deviation 33.23 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 CD40L - A/Indonesia, Month 12 | 1505.73 cells/million T-cells | Standard Deviation 985.99 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 CD40L - A/Vietnam, Month 6 + 21 Days | 1480.21 cells/million T-cells | Standard Deviation 1520.92 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 CD40L - A/Vietnam, Month 12 | 1474.26 cells/million T-cells | Standard Deviation 1073.1 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 CD40L - A/Indonesia, Month 12 | 9.05 cells/million T-cells | Standard Deviation 186.92 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 CD40L - A/Indonesia, Month 18 | 1975.69 cells/million T-cells | Standard Deviation 1126.07 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 CD40L- A/Vietnam, Month 18 | 1640.12 cells/million T-cells | Standard Deviation 1252.01 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IFN-γ - A/Vietnam, Month 18 | 5.22 cells/million T-cells | Standard Deviation 95.47 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IL-2 - A/Vietnam, Day 0 | 230.40 cells/million T-cells | Standard Deviation 360.46 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 CD40L - A/Vietnam, Month 6 | 867.92 cells/million T-cells | Standard Deviation 591.04 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IFN-γ - A/Vietnam, Day 0 | 24.17 cells/million T-cells | Standard Deviation 183.45 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IL-2 - A/Vietnam, Month 6 | 648.07 cells/million T-cells | Standard Deviation 584.83 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 CD40L - A/Vietnam, Month 12 | 5.10 cells/million T-cells | Standard Deviation 65.14 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IL-2 - A/Vietnam, Month 6 + 7 Days | 1390.30 cells/million T-cells | Standard Deviation 1480.2 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 CD40L - A/Vietnam, Day 0 | 387.68 cells/million T-cells | Standard Deviation 458.4 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IL-2 - A/Vietnam, Month 6 + 21 Days | 965.41 cells/million T-cells | Standard Deviation 1302.89 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IL-2 - A/Indonesia, Month 12 | 1278.49 cells/million T-cells | Standard Deviation 908.04 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 All Doubles - A/Vietnam, Month 18 | 1676.20 cells/million T-cells | Standard Deviation 1267.85 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IL-2 - A/Indonesia, Month 18 | 66.29 cells/million T-cells | Standard Deviation 1268.66 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IL-2 - A/Vietnam, Month 12 | 1264.64 cells/million T-cells | Standard Deviation 1008.46 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 CD40L - A/Indonesia, Month 18 | 5.25 cells/million T-cells | Standard Deviation 71.46 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IL-2 - A/Indonesia, Month 18 | 1480.68 cells/million T-cells | Standard Deviation 1040.08 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 All Doubles - A/Indonesia, Month 18 | 1978.73 cells/million T-cells | Standard Deviation 1138.17 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IL-2- A/Vietnam, Month 18 | 1434.59 cells/million T-cells | Standard Deviation 1156.89 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IFN-γ - A/Indonesia, Month 18 | 4.61 cells/million T-cells | Standard Deviation 83.81 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IFN-γ - A/Vietnam, Day 0 | 275.09 cells/million T-cells | Standard Deviation 299.79 |
| GSK1562902A 2V/I/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 All Doubles - A/Vietnam, Month 12 | 1506.94 cells/million T-cells | Standard Deviation 1086.61 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IFN-γ - A/Vietnam, Month 6 | 10.92 cells/million T-cells | Standard Deviation 133.43 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 CD40L - A/Indonesia, Month 12 | 7.74 cells/million T-cells | Standard Deviation 144.04 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IFN-γ - A/Vietnam, Month 6 | 543.11 cells/million T-cells | Standard Deviation 607.67 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 All Doubles - A/Indonesia, Month 12 | 1243.41 cells/million T-cells | Standard Deviation 1434.39 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 All Doubles - A/Vietnam, Month 12 | 14.09 cells/million T-cells | Standard Deviation 771.65 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 TNF-α - A/Vietnam, Month 6 + 7 Days | 27.99 cells/million T-cells | Standard Deviation 151.32 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IFN-γ - A/Vietnam, Month 6 + 7 Days | 887.74 cells/million T-cells | Standard Deviation 412.3 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 All Doubles - A/Vietnam, Month 18 | 1560.54 cells/million T-cells | Standard Deviation 1546.7 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 CD40L - A/Vietnam, Month 18 | 3.07 cells/million T-cells | Standard Deviation 40 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 CD40L- A/Vietnam, Month 18 | 1518.75 cells/million T-cells | Standard Deviation 1489.22 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IFN-γ - A/Vietnam, Month 6 + 21 Days | 908.75 cells/million T-cells | Standard Deviation 952.74 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 All Doubles - A/Vietnam, Month 6 + 21 Days | 1953.30 cells/million T-cells | Standard Deviation 2219.16 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IFN-γ - A/Vietnam, Month 12 | 4.42 cells/million T-cells | Standard Deviation 56.81 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 All Doubles - A/Indonesia, Month 18 | 34.07 cells/million T-cells | Standard Deviation 1414.34 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IFN-γ - A/Indonesia, Month 12 | 746.33 cells/million T-cells | Standard Deviation 727.94 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 CD40L - A/Vietnam, Month 6 | 1046.99 cells/million T-cells | Standard Deviation 893.54 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IL-2 - A/Indonesia, Month 12 | 28.61 cells/million T-cells | Standard Deviation 1566.57 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IFN-γ - A/Indonesia, Month 18 | 3.73 cells/million T-cells | Standard Deviation 97.93 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IFN-γ - A/Vietnam, Month 12 | 832.49 cells/million T-cells | Standard Deviation 1138.08 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 All Doubles - A/Vietnam, Month 6 + 7 Days | 1769.33 cells/million T-cells | Standard Deviation 1024.5 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 All Doubles - A/Vietnam, Month 18 | 11.17 cells/million T-cells | Standard Deviation 676.65 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 TNF-α - A/Vietnam, Month 6 | 20.44 cells/million T-cells | Standard Deviation 140.65 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IFN-γ - A/Indonesia, Month 18 | 883.75 cells/million T-cells | Standard Deviation 969.2 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IL-2- A/Vietnam, Month 18 | 1140.29 cells/million T-cells | Standard Deviation 1374.45 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IL-2 - A/Vietnam, Day 0 | 27.00 cells/million T-cells | Standard Deviation 258.14 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IL-2 - A/Vietnam, Day 0 | 289.83 cells/million T-cells | Standard Deviation 385.44 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IFN-γ - A/Vietnam, Month 18 | 949.06 cells/million T-cells | Standard Deviation 949.59 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 All Doubles - A/Vietnam, Month 6 | 1071.19 cells/million T-cells | Standard Deviation 923.45 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 CD40L - A/Vietnam, Day 0 | 6.15 cells/million T-cells | Standard Deviation 165.75 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IL-2 - A/Indonesia, Month 12 | 1041.21 cells/million T-cells | Standard Deviation 1250.37 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 TNF-α - A/Vietnam, Day 0 | 262.12 cells/million T-cells | Standard Deviation 309.11 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IL-2 - A/Indonesia, Month 18 | 1248.66 cells/million T-cells | Standard Deviation 1383.46 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IFN-γ - A/Vietnam, Day 0 | 23.68 cells/million T-cells | Standard Deviation 347.01 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 All Doubles - A/Vietnam, Month 12 | 1220.87 cells/million T-cells | Standard Deviation 2280.45 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 TNF-α - A/Vietnam, Month 6 | 684.19 cells/million T-cells | Standard Deviation 700.61 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 All Doubles - A/Vietnam, Day 0 | 469.25 cells/million T-cells | Standard Deviation 470.89 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 CD40L - A/Vietnam, Month 6 | 4.81 cells/million T-cells | Standard Deviation 49.19 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 TNF-α - A/Vietnam, Day 0 | 35.35 cells/million T-cells | Standard Deviation 219.77 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 TNF-α - A/Vietnam, Month 6 + 7 Days | 972.71 cells/million T-cells | Standard Deviation 668.12 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IL-2 - A/Vietnam, Month 6 | 719.07 cells/million T-cells | Standard Deviation 763.89 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IL-2 - A/Vietnam, Month 6 | 25.91 cells/million T-cells | Standard Deviation 102.37 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 CD40L - A/Vietnam, Day 0 | 441.16 cells/million T-cells | Standard Deviation 460.09 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 TNF-α - A/Vietnam, Month 6 + 21 Days | 1227.63 cells/million T-cells | Standard Deviation 1871.42 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 TNF-α - A/Vietnam, Month 18 | 9.31 cells/million T-cells | Standard Deviation 642.97 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IFN-γ - A/Indonesia, Month 12 | 2.83 cells/million T-cells | Standard Deviation 38.52 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 CD40L - A/Vietnam, Month 6 + 7 Days | 5.92 cells/million T-cells | Standard Deviation 45.82 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 TNF-α - A/Indonesia, Month 12 | 1148.53 cells/million T-cells | Standard Deviation 1208.96 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 CD40L - A/Indonesia, Month 18 | 3.66 cells/million T-cells | Standard Deviation 56.08 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IL-2 - A/Vietnam, Month 12 | 13.31 cells/million T-cells | Standard Deviation 773.02 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IL-2 - A/Vietnam, Month 12 | 999.23 cells/million T-cells | Standard Deviation 2005.29 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 TNF-α - A/Vietnam, Month 12 | 1096.87 cells/million T-cells | Standard Deviation 1906.75 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 TNF-α - A/Indonesia, Month 18 | 34.37 cells/million T-cells | Standard Deviation 1369.22 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 CD40L - A/Vietnam, Month 6 + 21 Days | 3.21 cells/million T-cells | Standard Deviation 30.61 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 CD40L - A/Vietnam, Month 6 + 21 Days | 1880.07 cells/million T-cells | Standard Deviation 2151.87 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 TNF-α - A/Indonesia, Month 18 | 1224.50 cells/million T-cells | Standard Deviation 1267.2 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IFN-γ - A/Vietnam, Month 18 | 3.15 cells/million T-cells | Standard Deviation 107.32 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IL-2 - A/Vietnam, Month 6 + 7 Days | 26.46 cells/million T-cells | Standard Deviation 113.81 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IL-2 - A/Vietnam, Month 6 + 7 Days | 1147.31 cells/million T-cells | Standard Deviation 980.42 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 TNF-α - A/Vietnam, Month 18 | 1147.21 cells/million T-cells | Standard Deviation 1402.58 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 TNF-α - A/Vietnam, Month 12 | 12.30 cells/million T-cells | Standard Deviation 725.71 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 CD40L - A/Indonesia, Month 12 | 1221.20 cells/million T-cells | Standard Deviation 1371.18 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 All Doubles - A/Indonesia, Month 18 | 1550.40 cells/million T-cells | Standard Deviation 1557.3 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 All Doubles - A/Vietnam, Day 0 | 45.07 cells/million T-cells | Standard Deviation 377.44 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IFN-γ - A/Vietnam, Month 6 + 7 days | 12.90 cells/million T-cells | Standard Deviation 96.83 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IL-2 - A/Vietnam, Month 18 | 9.50 cells/million T-cells | Standard Deviation 678.33 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 CD40L - A/Vietnam, Month 12 | 3.35 cells/million T-cells | Standard Deviation 47.52 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 All Doubles - A/Vietnam, Month 6 | 40.43 cells/million T-cells | Standard Deviation 148.42 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 TNF-α - A/Indonesia, Month 12 | 31.65 cells/million T-cells | Standard Deviation 1425.49 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 CD40L - A/Vietnam, Month 12 | 1152.29 cells/million T-cells | Standard Deviation 2263.92 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 CD40L - A/Vietnam, Month 6 + 7 Days | 1717.69 cells/million T-cells | Standard Deviation 990.51 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 All Doubles - A/Vietnam, Month 6 + 7 Days | 32.56 cells/million T-cells | Standard Deviation 150.48 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IFN-γ - A/Vietnam, Day 0 | 331.35 cells/million T-cells | Standard Deviation 379.46 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IL-2 - A/Vietnam, Month 6 + 21 Days | 13.48 cells/million T-cells | Standard Deviation 93.72 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 IL-2 - A/Vietnam, Month 6 + 21 Days | 1380.65 cells/million T-cells | Standard Deviation 1761.07 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 All Doubles - A/Vietnam, Month 6 + 21 Days | 16.93 cells/million T-cells | Standard Deviation 105.56 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 TNF-α - A/Vietnam, Month 6 + 21 Days | 11.99 cells/million T-cells | Standard Deviation 83.27 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IFN-γ - A/Vietnam, Month 6 + 21 Days | 11.37 cells/million T-cells | Standard Deviation 82.16 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD4 CD40L - A/Indonesia, Month 18 | 1522.12 cells/million T-cells | Standard Deviation 1553.48 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 All Doubles - A/Indonesia, Month 12 | 36.18 cells/million T-cells | Standard Deviation 1567.28 |
| GSK1562902A 2V/V/6 Group | Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 | CD8 IL-2 - A/Indonesia, Month 18 | 33.60 cells/million T-cells | Standard Deviation 1414.79 |
Secondary
GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12
GMTs were calculated for H5N1 HI antibodies against the A/Vietnam/1194/2004 or A/Indonesia/05/2005 strains.
Time frame: At Day 0, Day 21, Day 42, Month 6, Month 12, Month 12 + 7 Days, Month 12 + 21 Days and at Month 18
Population: This analysis was performed on the ATP Cohort for Immunogenicity and ATP Cohort for Persistence (only for Month 18), which included all evaluable subjects for whom immunogenicity were available and who complied with the inclusion/exclusion criteria defined in the protocol. Day 42 data were available only from subjects who received 3 vaccine doses.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 | 5.8 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Day 21 | 6.8 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 18 | 139.3 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 139.3 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 97.8 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 18 | 115.8 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 235.9 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Day 0 | 5.0 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 | 8.4 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 6 | 13.2 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 6 | 5.7 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 352.6 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Day 21 | 22.1 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Day 0 | 5.0 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 | 9.9 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Day 0 | 5.0 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Day 21 | 6.3 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 6 | 5.4 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 | 5.9 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 196.2 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 420.0 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 18 | 56.6 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Day 0 | 5.1 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Day 21 | 17.6 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 6 | 10.6 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 354.3 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 662.2 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 18 | 76.1 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 18 | 337.5 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 441.0 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Day 0 | 5.1 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 6 | 10.2 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Day 21 | 21.4 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Day 42 | 239.4 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Day 0 | 5.0 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 6 | 38.4 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Day 42 | 28.0 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 | 14.2 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Day 21 | 6.0 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 257.7 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 106.5 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 191.9 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 | 5.7 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 18 | 385.9 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 624.9 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 18 | 121.3 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 6 | 6.5 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Day 21 | 5.3 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 239.4 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Day 0 | 5.2 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 | 17.4 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 942.2 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 | 8.4 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Day 21 | 15.8 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 18 | 149.3 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Day 42 | 178.3 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Day 42 | 18.6 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Day 0 | 5.0 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 358.2 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 6 | 24.0 Titers |
Secondary
GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6
GMTs were calculated for H5N1 HI antibodies against the A/Vietnam/1194/2004 or A/Indonesia/05/2005 strains.
Time frame: At Day 0, Day 21, Day 42, Month 6, Month 6+ 7 Days, Month 6+ 21 Days, Month 12 and at Month 18
Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Persistence, which included all evaluable subjects for whom long term immunogenicity data were available and who complied with the inclusion/exclusion criteria defined in the protocol. Day 42 data were available only from subjects who received 3 vaccine doses.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 18 | 31.1 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 7 Days | 142.6 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 | 11.6 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 21 | 20.7 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 0 | 5.0 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 21 | 6.5 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 0 | 5.0 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 18 | 24.3 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 21 Days | 290.8 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 | 5.5 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 12 | 66.0 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 21 Days | 411.1 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 12 | 44.6 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 7 Days | 209.0 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 18 | 25.7 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 | 5.3 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 21 Days | 97.9 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 12 | 17.6 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 18 | 19.8 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 0 | 5.2 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 21 | 15.8 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 | 9.7 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 7 Days | 215.4 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 21 Days | 317.4 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 12 | 63.8 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 0 | 5.0 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 21 | 5.6 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 7 Days | 64.5 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 18 | 50.6 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 | 29.6 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 18 | 45.1 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 42 | 22.5 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 7 Days | 124.1 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 12 | 56.6 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 0 | 5.0 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 21 Days | 542.1 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 0 | 5.2 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 7 Days | 191.0 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 21 Days | 383.5 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 | 8.5 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 21 | 6.3 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 21 | 34.3 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 12 | 107.1 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 42 | 220.6 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 7 Days | 59.9 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 21 | 5.4 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 | 31.3 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 12 | 23.8 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 7 Days | 211.7 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 21 Days | 120.9 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 42 | 16.7 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 21 Days | 359.2 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 42 | 275.1 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 0 | 5.0 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 18 | 46.4 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 | 7.0 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 0 | 5.8 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 18 | 28.3 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 12 | 101.6 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 21 | 30.8 Titers |
Secondary
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12
GMTs were calculated for H5N1 neutralizing antibodies against the A/Vietnam/1194/2004 or A/Indonesia/05/2005 strains.
Time frame: At Day 0, Day 21, Day 42, Month 6, Month 12, Month 12 + 7 Days and Month 12 + 21 Days
Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol. Day 42 data were available only from subjects who received 3 vaccine doses.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Vietnam, Day 21 | 124.4 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 1848.1 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 | 124.7 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Vietnam, Day 0 | 21.0 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Indonesia, Day 21 | 43.5 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 3209.7 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 2025.2 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Indonesia, Day 0 | 15.8 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Vietnam, Month 6 | 270.6 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 | 551.9 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 3254.2 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Indonesia, Month 6 | 144.2 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 1301.5 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Vietnam, Month 6 | 223.2 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Vietnam, Day 0 | 20.6 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Vietnam, Day 21 | 99.2 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Indonesia, Month 6 | 122.4 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 1448.5 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 2520.3 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 | 106.5 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 | 504.0 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 936.9 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Indonesia, Day 21 | 37.0 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Indonesia, Day 0 | 15.7 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Vietnam, Day 21 | 80.2 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Indonesia, Day 0 | 15.1 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Indonesia, Day 21 | 31.3 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Indonesia, Day 42 | 97.0 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Indonesia, Month 6 | 259.6 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 | 234.6 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 2556.6 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 4602.2 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Vietnam, Day 0 | 20.3 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Vietnam, Day 42 | 500.2 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Vietnam, Month 6 | 401.9 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 | 474.3 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 2002.2 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 3874.7 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Indonesia, Day 21 | 26.5 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Vietnam, Month 6 | 334.2 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 1102.4 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 | 197.5 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Indonesia, Day 0 | 15.5 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 | 468.1 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Indonesia, Month 6 | 196.3 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Indonesia, Day 42 | 83.6 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 2304.8 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Vietnam, Day 21 | 104.6 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 1718.1 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Vietnam, Day 42 | 404.4 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Vietnam, Day 0 | 20.0 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 1708.3 Titers |
Secondary
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6
GMTs were calculated for H5N1 neutralizing antibodies against the A/Vietnam/1194/2004 or A/Indonesia/05/2005 strains.
Time frame: At Day 0, Day 21, Day 42, Month 6, Month 6 + 7 Days, Month 6 + 21 Days and Month 12
Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol. Day 42 data were available only from subjects who received 3 vaccine doses.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Indonesia, Day 0 | 15.7 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 21 Days | 1392.3 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 7 Days | 966.7 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Vietnam, Day 0 | 20.4 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Indonesia, Day 21 | 39.8 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Vietnam, Month 12 | 646.3 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 21 Days | 1815.5 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 | 39.7 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 | 22.0 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 7 Days | 778.7 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Indonesia, Month 12 | 672.9 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Vietnam, Day 21 | 117.9 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Indonesia, Month 12 | 392.1 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 | 39.2 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Vietnam, Day 0 | 22.2 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Vietnam, Day 21 | 106.7 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Vietnam, Month 12 | 762.9 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 21 Days | 1435.9 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 | 21.7 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 7 Days | 512.4 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 7 Days | 1113.9 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 21 Days | 674.4 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Indonesia, Day 21 | 32.0 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Indonesia, Day 0 | 15.5 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 | 41.7 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Indonesia, Day 0 | 15.4 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Indonesia, Day 21 | 37.9 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Indonesia, Day 42 | 87.9 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 7 Days | 1016.1 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 21 Days | 2334.1 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Indonesia, Month 12 | 1003.8 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Vietnam, Day 0 | 18.9 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Vietnam, Day 21 | 179.6 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Vietnam, Day 42 | 372.3 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 | 88.8 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 7 Days | 945.3 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 21 Days | 1922.0 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Vietnam, Month 12 | 795.6 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Indonesia, Day 21 | 33.3 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 | 91.2 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 21 Days | 831.3 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 7 Days | 562.0 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Indonesia, Day 0 | 14.4 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 7 Days | 1058.8 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 | 30.5 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Indonesia, Day 42 | 75.9 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Vietnam, Month 12 | 823.6 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Vietnam, Day 21 | 78.8 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 21 Days | 1625.2 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Vietnam, Day 42 | 429.8 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Vietnam, Day 0 | 19.8 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 | A/Indonesia, Month 12 | 540.0 Titers |
Secondary
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12
GMTs were calculated for H5N1 neutralizing antibodies against the A/Vietnam/1194/2004 or A/Indonesia/05/2005 strains.
Time frame: At Day 0, Day 21, Day 42, Month 6, Month 12, Month 12 + 7 Days, Month 12 + 21 Days and Month 18
Population: The analysis was performed on the ATP Cohort for Persistence, which included all evaluable subjects for whom long term immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol. Day 42 data were available only from subjects who received 3 vaccine doses.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 18 | 903.0 Titer |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 3722.1 Titer |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 | 127.0 Titer |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 18 | 813.2 Titer |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 2190.6 Titer |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 3490.4 Titer |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Day 21 | 45.1 Titer |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Day 21 | 123.7 Titer |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 1945.3 Titer |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 | 542.7 Titer |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 6 | 274.5 Titer |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Day 0 | 20.5 Titer |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 6 | 146.5 Titer |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Day 0 | 15.9 Titer |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Day 21 | 40.0 Titer |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Day 21 | 103.6 Titer |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Day 0 | 15.6 Titer |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 6 | 123.3 Titer |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 | 107.8 Titer |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 947.5 Titer |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 1303.0 Titer |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 18 | 423.7 Titer |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Day 0 | 20.8 Titer |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 6 | 223.1 Titer |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 | 511.2 Titer |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 1435.4 Titer |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 2495.4 Titer |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 18 | 585.9 Titer |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Day 21 | 80.2 Titer |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Day 0 | 15.4 Titer |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 | 475.9 Titer |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 18 | 1708.9 Titer |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Day 21 | 31.3 Titer |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Day 42 | 469.2 Titer |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 1972.2 Titer |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 4057.4 Titer |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 | 231.3 Titer |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Day 42 | 100.8 Titer |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 2476.1 Titer |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Day 0 | 20.8 Titer |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 6 | 405.1 Titer |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 18 | 1650.0 Titer |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 4661.0 Titer |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 6 | 255.0 Titer |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 1708.3 Titer |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 18 | 620.6 Titer |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Day 42 | 80.7 Titer |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Day 0 | 20.5 Titer |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Day 21 | 116.2 Titer |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Day 42 | 399.2 Titer |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 2304.8 Titer |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 6 | 334.2 Titer |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Day 21 | 26.3 Titer |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 | 468.1 Titer |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 18 | 871.9 Titer |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 | 197.5 Titer |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 1718.1 Titer |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 1102.4 Titer |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 6 | 196.3 Titer |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Day 0 | 15.7 Titer |
Secondary
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6
GMTs were calculated for H5N1 neutralizing antibodies against the A/Vietnam/1194/2004 or A/Indonesia/05/2005 strains.
Time frame: At Day 0, Day 21, Day 42, Month 6, Month 6 + 7 Days, Month 6 + 21 Days, Month 12 and Month 18
Population: The analysis was performed on the ATP Cohort for Persistence, which included all evaluable subjects for whom long term immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol. Day 42 data were available only from subjects who received 3 vaccine doses.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6+ 7 Days | 906.1 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 21 | 40.6 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 18 | 361.1 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 12 | 678.0 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 21 Days | 1703.0 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 18 | 277.7 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 21 Days | 1296.1 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 0 | 15.7 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 7 Days | 727.6 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 | 35.9 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 | 20.7 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 12 | 643.3 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 21 | 119.0 Titers |
| GSK1562902A V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 0 | 20.9 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 7 Days | 1167.5 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 0 | 15.3 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 21 | 31.8 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 | 22.2 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6+ 7 Days | 526.2 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 21 Days | 707.6 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 12 | 392.1 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 18 | 225.0 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 0 | 22.0 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 21 | 109.0 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 | 39.8 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 21 Days | 1568.2 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 12 | 762.9 Titers |
| GSK1562902A V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 18 | 338.1 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 18 | 358.9 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 12 | 797.7 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 0 | 19.3 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 | 40.9 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 21 | 179.6 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 42 | 352.9 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 0 | 15.5 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 | 86.1 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 42 | 86.3 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 7 Days | 910.3 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 21 | 37.9 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 21 Days | 1863.6 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 21 Days | 2224.0 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 12 | 995.8 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6+ 7 Days | 963.3 Titers |
| GSK1562902A 2V/I/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 18 | 447.6 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 12 | 533.4 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 18 | 290.1 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 | 29.2 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 21 | 36.4 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 21 Days | 814.7 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 0 | 20.4 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 7 Days | 1035.0 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 12 | 844.7 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6+ 7 Days | 537.3 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 21 | 103.6 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 18 | 444.5 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 42 | 449.3 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 42 | 76.7 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 0 | 14.4 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 21 Days | 1609.1 Titers |
| GSK1562902A 2V/V/6 Group | GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 | 91.4 Titers |
Secondary
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, A/Vietnam/1194/2004 and A/Indonesia/5/2005, for Groups Who Received Booster Dose at Month 12
Booster seroconversion (SCR) was defined as: For seronegative subjects at pre-booster (Month 12), antibody titer ≥ 1:40 at Month 12 + 7 days; For seropositive subjects at pre-booster (Month 12), antibody titer at Month 12 + 7 days ≥ 4 fold the pre-vaccination antibody titer at Month 12.
Time frame: At Month 12 + 7 Days, Month 12 + 21 Days and Month 18
Population: This analysis was performed on the ATP Cohort for Immunogenicity and ATP Cohort for Persistence (only for M18), which included all evaluable subjects for whom immunogenicity data/long term immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, A/Vietnam/1194/2004 and A/Indonesia/5/2005, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 38 Participants |
| GSK1562902A V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, A/Vietnam/1194/2004 and A/Indonesia/5/2005, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 41 Participants |
| GSK1562902A V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, A/Vietnam/1194/2004 and A/Indonesia/5/2005, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 18 | 39 Participants |
| GSK1562902A V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, A/Vietnam/1194/2004 and A/Indonesia/5/2005, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 43 Participants |
| GSK1562902A V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, A/Vietnam/1194/2004 and A/Indonesia/5/2005, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 44 Participants |
| GSK1562902A V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, A/Vietnam/1194/2004 and A/Indonesia/5/2005, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 18 | 30 Participants |
| GSK1562902A V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, A/Vietnam/1194/2004 and A/Indonesia/5/2005, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 18 | 33 Participants |
| GSK1562902A V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, A/Vietnam/1194/2004 and A/Indonesia/5/2005, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 46 Participants |
| GSK1562902A V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, A/Vietnam/1194/2004 and A/Indonesia/5/2005, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 43 Participants |
| GSK1562902A V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, A/Vietnam/1194/2004 and A/Indonesia/5/2005, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 18 | 34 Participants |
| GSK1562902A V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, A/Vietnam/1194/2004 and A/Indonesia/5/2005, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 49 Participants |
| GSK1562902A V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, A/Vietnam/1194/2004 and A/Indonesia/5/2005, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 50 Participants |
| GSK1562902A 2V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, A/Vietnam/1194/2004 and A/Indonesia/5/2005, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 36 Participants |
| GSK1562902A 2V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, A/Vietnam/1194/2004 and A/Indonesia/5/2005, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 18 | 37 Participants |
| GSK1562902A 2V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, A/Vietnam/1194/2004 and A/Indonesia/5/2005, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 34 Participants |
| GSK1562902A 2V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, A/Vietnam/1194/2004 and A/Indonesia/5/2005, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 18 | 34 Participants |
| GSK1562902A 2V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, A/Vietnam/1194/2004 and A/Indonesia/5/2005, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 37 Participants |
| GSK1562902A 2V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, A/Vietnam/1194/2004 and A/Indonesia/5/2005, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 34 Participants |
| GSK1562902A 2V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, A/Vietnam/1194/2004 and A/Indonesia/5/2005, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 43 Participants |
| GSK1562902A 2V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, A/Vietnam/1194/2004 and A/Indonesia/5/2005, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 18 | 29 Participants |
| GSK1562902A 2V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, A/Vietnam/1194/2004 and A/Indonesia/5/2005, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 43 Participants |
| GSK1562902A 2V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, A/Vietnam/1194/2004 and A/Indonesia/5/2005, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 38 Participants |
| GSK1562902A 2V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, A/Vietnam/1194/2004 and A/Indonesia/5/2005, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 39 Participants |
| GSK1562902A 2V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, A/Vietnam/1194/2004 and A/Indonesia/5/2005, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 18 | 34 Participants |
Secondary
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12
Booster seroconversion (SCR) was defined as: For seronegative subjects at pre-booster (Month 12), antibody titer ≥ 1:40 at Month 12 + 7 days; For seropositive subjects at pre-booster (Month 12), antibody titer at Month 12 + 7 days ≥ 4 fold the pre-vaccination antibody titer at Month 12. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/5/2005.
Time frame: At Month 12 + 7 Days, Month 12 + 21 Days and Month 18
Population: The analysis was performed on the ATP Cohort for Persistence, which included all evaluable subjects for whom long term immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 39 Participants |
| GSK1562902A V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 44 Participants |
| GSK1562902A V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 18 | 33 Participants |
| GSK1562902A V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 15 Participants |
| GSK1562902A V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 30 Participants |
| GSK1562902A V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 18 | 8 Participants |
| GSK1562902A V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 18 | 7 Participants |
| GSK1562902A V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 15 Participants |
| GSK1562902A V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 34 Participants |
| GSK1562902A V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 18 | 25 Participants |
| GSK1562902A V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 38 Participants |
| GSK1562902A V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 23 Participants |
| GSK1562902A 2V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 39 Participants |
| GSK1562902A 2V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 18 | 31 Participants |
| GSK1562902A 2V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 17 Participants |
| GSK1562902A 2V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 18 | 16 Participants |
| GSK1562902A 2V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 29 Participants |
| GSK1562902A 2V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 32 Participants |
| GSK1562902A 2V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 21 Participants |
| GSK1562902A 2V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 18 | 10 Participants |
| GSK1562902A 2V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 29 Participants |
| GSK1562902A 2V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 19 Participants |
| GSK1562902A 2V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 20 Participants |
| GSK1562902A 2V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 18 | 18 Participants |
Secondary
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12
Booster seroconversion (SCR) was defined as: For seronegative subjects at pre-booster (Month 12), antibody titer ≥ 1:40 at Month 12 + 7 days; For seropositive subjects at pre-booster (Month 12), antibody titer at Month 12 + 7 days ≥ 4 fold the pre-vaccination antibody titer at Month 12. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/5/2005.
Time frame: At Month 12 + 7 Days and Month 12 + 21 Days
Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 42 Participants |
| GSK1562902A V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 46 Participants |
| GSK1562902A V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 17 Participants |
| GSK1562902A V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 31 Participants |
| GSK1562902A V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 39 Participants |
| GSK1562902A V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 16 Participants |
| GSK1562902A V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 25 Participants |
| GSK1562902A V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 35 Participants |
| GSK1562902A 2V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 18 Participants |
| GSK1562902A 2V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 42 Participants |
| GSK1562902A 2V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 31 Participants |
| GSK1562902A 2V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 34 Participants |
| GSK1562902A 2V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 21 Participants |
| GSK1562902A 2V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 29 Participants |
| GSK1562902A 2V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 20 Participants |
| GSK1562902A 2V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 19 Participants |
Secondary
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6
Booster SCR was defined as: For seronegative subjects at pre-booster (Month 6), antibody titer ≥ 1:40 at Month 6 + 7 days; For seropositive subjects at pre-booster (Month 6), antibody titer at Month 6 + 7 days ≥ 4 fold the pre-vaccination antibody titer at Month 6. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/5/2005.
Time frame: At Month 6 + 7 Days, Month 6 + 21 Days, Month 12 and Month 18
Population: This analysis was performed on the ATP Cohort for Immunogenicity (only for M12) and ATP Cohort for Persistence, which included all evaluable subjects for whom immunogenicity data/long term immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 7 Days | 48 Participants |
| GSK1562902A V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 21 Days | 46 Participants |
| GSK1562902A V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 12 | 47 Participants |
| GSK1562902A V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 18 | 40 Participants |
| GSK1562902A V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 7 Days | 44 Participants |
| GSK1562902A V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 21 Days | 46 Participants |
| GSK1562902A V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 12 | 46 Participants |
| GSK1562902A V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 18 | 33 Participants |
| GSK1562902A V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 21 Days | 41 Participants |
| GSK1562902A V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 7 Days | 40 Participants |
| GSK1562902A V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 21 Days | 41 Participants |
| GSK1562902A V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 18 | 35 Participants |
| GSK1562902A V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 12 | 39 Participants |
| GSK1562902A V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 18 | 32 Participants |
| GSK1562902A V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 12 | 40 Participants |
| GSK1562902A V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 7 Days | 41 Participants |
| GSK1562902A 2V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 12 | 33 Participants |
| GSK1562902A 2V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 12 | 44 Participants |
| GSK1562902A 2V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 18 | 38 Participants |
| GSK1562902A 2V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 7 Days | 35 Participants |
| GSK1562902A 2V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 21 Days | 39 Participants |
| GSK1562902A 2V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 18 | 26 Participants |
| GSK1562902A 2V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 7 Days | 43 Participants |
| GSK1562902A 2V/I/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 21 Days | 45 Participants |
| GSK1562902A 2V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 12 | 41 Participants |
| GSK1562902A 2V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 18 | 32 Participants |
| GSK1562902A 2V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 21 Days | 39 Participants |
| GSK1562902A 2V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 7 Days | 41 Participants |
| GSK1562902A 2V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 7 Days | 38 Participants |
| GSK1562902A 2V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 18 | 27 Participants |
| GSK1562902A 2V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 12 | 36 Participants |
| GSK1562902A 2V/V/6 Group | Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 21 Days | 40 Participants |
Secondary
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12
A seroconverted (SCR) subject was defined as a vaccinated subject who had either a pre-vaccination titer \< 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and at least a four-fold increase in post-vaccination titer. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/5/2005.
Time frame: At Day 21, Day 42, Month 6, Month 12, Month 12 + 7 Days, Month 12 + 21 Days
Population: This analysis was performed on the ATP Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol. Day 42 data were available only from subjects who received 3 vaccine doses.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 45 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 42 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 40 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 | 6 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 6 | 15 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 6 | 0 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 46 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Day 21 | 26 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Day 21 | 5 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 | 6 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 | 2 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 6 | 1 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Day 21 | 3 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 44 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 49 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Day 21 | 24 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 6 | 10 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 | 10 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 49 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 50 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 37 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 6 | 7 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Day 21 | 25 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Day 42 | 44 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Day 21 | 1 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 6 | 35 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Day 42 | 24 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 | 9 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 38 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 34 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 36 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 39 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 43 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 43 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 40 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 6 | 1 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Day 21 | 16 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 | 17 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Day 42 | 43 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Day 42 | 20 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Day 21 | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 | 5 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 6 | 24 Participants |
Secondary
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12
Seroconversion defined as: For initially seronegative subjects, antibody titer ≥ 1:40 after vaccination; For initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/05/2005.
Time frame: At Month 12 + 7 Days, Month 12 + 21 Days and Month 18
Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Persistence, which included all evaluable subjects for whom ilong term immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 47 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 18 | 30 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 46 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 18 | 39 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 43 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 40 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 39 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 37 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 18 | 34 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 42 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 18 | 33 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 41 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 36 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 40 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 40 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 35 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 18 | 34 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 18 | 37 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 18 | 29 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 34 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 36 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 18 | 34 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 34 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 37 Participants |
Secondary
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6
A seroconverted (SCR) subject was defined as a vaccinated subject who had either a pre-vaccination titer \<1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 2 flu strains assessed were A/Vietnam/1194/2004 (H5N1) and A/Indonesia/5/2005 (H5N1).
Time frame: At Day 21, Day 42, Month 6, Month 6 + 7 Days, Month 6 + 21 Days, Month 12 and Month 18
Population: This analysis was performed on the ATP Cohort for Immunogenicity and ATP Cohort for Persistence (only for M6+D7/D21, M18), which included all evaluable subjects for whom immunogenicity data were available and who complied with the criteria defined in the protocol. Day 42 data were available only from subjects who received 3 vaccine doses.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 18 | 11 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 7 Days | 43 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 12 | 33 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 12 | 16 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 | 5 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 21 | 19 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 21 Days | 46 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 7 Days | 43 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 21 | 0 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 18 | 26 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 | 0 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 21 Days | 46 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 12 | 29 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 18 | 18 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 21 | 3 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 12 | 35 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 18 | 15 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 7 Days | 31 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 21 | 24 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 21 Days | 38 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 21 Days | 35 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 | 0 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 | 13 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 7 Days | 36 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 21 | 23 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 12 | 19 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 18 | 28 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 21 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 42 | 36 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 | 25 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 7 Days | 29 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 21 Days | 41 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 12 | 32 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 18 | 9 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 42 | 15 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 | 2 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 7 Days | 38 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 21 Days | 42 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 12 | 31 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 42 | 23 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 7 Days | 27 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 42 | 40 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 | 25 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 | 4 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 21 | 29 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 18 | 20 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 21 Days | 35 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 7 Days | 28 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 18 | 7 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 12 | 37 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 21 Days | 34 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 21 | 3 Participants |
Secondary
Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12
Seroconversion (SCR) was defined as the percentage of vaccinees with a minimum 4-fold increase in neutralizing antibody titer at the post-vaccination time-point compared to Day 0. The 2 flu strains assessed were A/Vietnam/1194/2004 (H5N1) and A/Indonesia/5/2005 (H5N1).
Time frame: At Day 21, Day 42, Month 6, Month 12, Month 12 + 7 Days and Month 12 + 21 Days
Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol. Day 42 data were available only from subjects who received 3 vaccine doses.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 6 | 45 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Day 21 | 40 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 | 48 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 6 | 51 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Day 21 | 19 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 | 41 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 51 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 51 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 50 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 50 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 49 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 | 49 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 | 39 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Day 21 | 38 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 6 | 44 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Day 21 | 17 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 50 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 6 | 50 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 49 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 50 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 41 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Day 21 | 1 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Day 42 | 35 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 6 | 43 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 | 42 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 42 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 43 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Day 21 | 4 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Day 42 | 43 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 6 | 40 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 | 43 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 42 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Day 21 | 5 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 40 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 39 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 | 40 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 40 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 12 | 40 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Month 6 | 44 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 40 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Day 42 | 32 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Day 42 | 45 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Indonesia, Day 21 | 1 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 | A/Vietnam, Month 6 | 41 Participants |
Secondary
Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6
Seroconversion (SCR) was defined as the percentage of vaccinees with a minimum 4-fold increase in neutralizing antibody titer at the post-vaccination time-point compared to Day 0. The 2 flu strains assessed were A/Vietnam/1194/2004 (H5N1) and A/Indonesia/5/2005 (H5N1).
Time frame: At Day 21, Day 42, Month 6, Month 6 + 7 Days, Month 6 + 21 Days and Month 12
Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol. Day 42 data were available only from subjects who received 3 vaccine doses.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 | 6 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 21 | 40 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 7 Days | 51 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 | 18 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 21 | 19 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 7 Days | 53 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 21 Days | 51 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 12 | 47 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 21 Days | 52 Participants |
| GSK1562902A V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 12 | 47 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 21 Days | 47 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 7 Days | 45 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 7 Days | 46 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 21 | 34 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 | 5 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 21 | 13 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 12 | 42 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 | 10 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 21 Days | 45 Participants |
| GSK1562902A V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 12 | 42 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 21 Days | 49 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 21 | 1 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 42 | 32 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 | 20 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 7 Days | 48 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 21 Days | 49 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 12 | 46 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 21 | 5 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 42 | 42 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 | 28 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 7 Days | 48 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 12 | 45 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 21 | 5 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 12 | 42 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 12 | 42 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 7 Days | 45 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 21 Days | 43 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 7 Days | 46 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 | 13 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 21 Days | 45 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 42 | 28 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 42 | 39 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 21 | 4 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 | 31 Participants |
Secondary
Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6
A seroprotected (SPR) subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40. The 2 flu strains assessed were A/Vietnam/1194/2004 (H5N1) and A/Indonesia/5/2005 (H5N1).
Time frame: At Day 0, Day 21, Day 42, Month 6, Month 6+ 7 Days, Month 6+ 21 Days, Month 12 and Month 18
Population: This analysis was performed on the ATP Cohort for Immunogenicity and ATP Cohort for Persistence (only for M18), which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria defined in the protocol. Day 42 data were available only from subjects who received 3 vaccine doses.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 7 Days | 32 Participants |
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 21 | 0 Participants |
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 18 | 26 Participants |
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 12 | 16 Participants |
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 21 Days | 37 Participants |
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 | 6 Participants |
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 12 | 33 Participants |
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 0 | 0 Participants |
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 21 Days | 40 Participants |
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 7 Days | 39 Participants |
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 | 0 Participants |
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 18 | 21 Participants |
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 21 | 19 Participants |
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 0 | 0 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 21 Days | 48 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 0 | 0 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 21 | 3 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 | 0 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 7 Days | 46 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 21 Days | 48 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 12 | 29 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 18 | 18 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 0 | 0 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 21 | 24 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 7 Days | 49 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 12 | 35 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 18 | 24 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 | 13 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 | 26 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 18 | 30 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 0 | 2 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 | 2 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 21 | 24 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 42 | 36 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 7 Days | 38 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 42 | 15 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 21 Days | 39 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 21 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 0 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 12 | 33 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 21 Days | 37 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 12 | 19 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 7 Days | 31 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 18 | 30 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 12 | 37 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 18 | 21 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 | 4 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 21 | 3 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 12 | 31 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 0 | 1 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 21 Days | 45 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 18 | 24 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 21 Days | 45 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 21 | 29 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Month 6 + 7 Days | 40 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 | 25 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 42 | 23 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Day 42 | 40 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Indonesia, Day 0 | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 | A/Vietnam, Month 6 + 7 Days | 42 Participants |
Secondary
Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12
A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40. The 2 flu strains assessed were A/Vietnam/1194/2004 (H5N1) and A/Indonesia/5/2005 (H5N1).
Time frame: At Day 0, Day 21, Day 42, Month 6, Month 12, Month 12 + 7 Days, Month 12 + 21 Days
Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol. Day 42 data were available only from subjects who received 3 vaccine doses.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Day 21 | 26 Participants |
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Day 0 | 0 Participants |
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 42 Participants |
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Month 12 | 2 Participants |
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Month 6 | 0 Participants |
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 46 Participants |
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 days | 45 Participants |
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Month 12 | 6 Participants |
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Day 21 | 5 Participants |
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Day 0 | 0 Participants |
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Month 6 | 15 Participants |
| GSK1562902A V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 40 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 44 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 days | 49 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 50 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 49 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Day 0 | 0 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Day 21 | 24 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Month 6 | 10 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Day 0 | 0 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Day 21 | 3 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Month 12 | 10 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Month 6 | 1 Participants |
| GSK1562902A V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Month 12 | 2 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 days | 37 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Day 0 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 38 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Month 12 | 9 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Day 42 | 24 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Day 42 | 45 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 36 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Month 6 | 36 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 34 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Month 12 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Day 0 | 0 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Day 21 | 1 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Month 6 | 7 Participants |
| GSK1562902A 2V/I/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Day 21 | 25 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Month 12 | 17 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Day 21 | 17 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Day 42 | 43 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Month 12 | 5 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Month 6 | 1 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Day 0 | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 43 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 39 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Month 6 | 24 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Day 21 | 0 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Day 42 | 20 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 43 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 days | 40 Participants |
| GSK1562902A 2V/V/6 Group | Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Day 0 | 0 Participants |
Secondary
Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12
The seroconversion factor (SCF) was defined as the fold change in serum hemagglutination inhibition (HI) geometric mean titers (GMTs) post-vaccination compared to Day 0. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/5/2005.
Time frame: At Day 21, Day 42, Month 6, Month 12, Month 12 + 7 Days, Month 12 + 21 Days
Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol. Day 42 data were available only from subjects who received 3 vaccine doses.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 70.9 Fold Increase |
| GSK1562902A V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Month 12 | 2.0 Fold Increase |
| GSK1562902A V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Month 12 | 1.2 Fold Increase |
| GSK1562902A V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Day 21 | 4.1 Fold Increase |
| GSK1562902A V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Month 6 | 2.6 Fold Increase |
| GSK1562902A V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Month 6 | 1.1 Fold Increase |
| GSK1562902A V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 132.4 Fold Increase |
| GSK1562902A V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 39.2 Fold Increase |
| GSK1562902A V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 84.0 Fold Increase |
| GSK1562902A V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Day 21 | 1.4 Fold Increase |
| GSK1562902A V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 27.9 Fold Increase |
| GSK1562902A V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 68.6 Fold Increase |
| GSK1562902A V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Month 12 | 1.6 Fold Increase |
| GSK1562902A V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 19.6 Fold Increase |
| GSK1562902A V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Month 6 | 2.1 Fold Increase |
| GSK1562902A V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Month 6 | 1.1 Fold Increase |
| GSK1562902A V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Day 21 | 3.6 Fold Increase |
| GSK1562902A V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Month 12 | 1.2 Fold Increase |
| GSK1562902A V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 45.9 Fold Increase |
| GSK1562902A V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Day 21 | 1.3 Fold Increase |
| GSK1562902A 2V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Month 6 | 7.5 Fold Increase |
| GSK1562902A 2V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Month 12 | 3.5 Fold Increase |
| GSK1562902A 2V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Month 6 | 2.0 Fold Increase |
| GSK1562902A 2V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Month 12 | 1.7 Fold Increase |
| GSK1562902A 2V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 47.9 Fold Increase |
| GSK1562902A 2V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Day 21 | 1.2 Fold Increase |
| GSK1562902A 2V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Day 42 | 5.9 Fold Increase |
| GSK1562902A 2V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 125.0 Fold Increase |
| GSK1562902A 2V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Day 21 | 3.8 Fold Increase |
| GSK1562902A 2V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Day 42 | 45.6 Fold Increase |
| GSK1562902A 2V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 71.6 Fold Increase |
| GSK1562902A 2V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 188.4 Fold Increase |
| GSK1562902A 2V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Month 12 + 21 Days | 38.4 Fold Increase |
| GSK1562902A 2V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Day 42 | 3.6 Fold Increase |
| GSK1562902A 2V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Month 6 | 4.6 Fold Increase |
| GSK1562902A 2V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Month 12 | 2.7 Fold Increase |
| GSK1562902A 2V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Day 21 | 1.1 Fold Increase |
| GSK1562902A 2V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Month 12 + 7 Days | 21.3 Fold Increase |
| GSK1562902A 2V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Month 12 + 21 Days | 84.5 Fold Increase |
| GSK1562902A 2V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Month 12 + 7 Days | 49.4 Fold Increase |
| GSK1562902A 2V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Month 12 | 1.1 Fold Increase |
| GSK1562902A 2V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Indonesia, Month 6 | 1.3 Fold Increase |
| GSK1562902A 2V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Day 42 | 34.4 Fold Increase |
| GSK1562902A 2V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 | A/Vietnam, Day 21 | 3.2 Fold Increase |
Secondary
Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6
The seroconversion factor (SCF) was defined as the fold change in serum hemagglutination inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0. The 2 flu strains assessed were A/Vietnam/1194/2004 (H5N1) and A/Indonesia/5/2005 (H5N1).
Time frame: At Day 21, Day 42, Month 6, Month 6 + 7 Days, Month 6 + 21 Days, Month 12 and Month 18
Population: This analysis was performed on the ATP Cohort for Immunogenicity and ATP Cohort for Persistence (only for M6+D7/D21, M18), which included all evaluable subjects for whom immunogenicity data were available and who complied with the criteria defined in the protocol. Day 42 data were available only from subjects who received 3 vaccine doses.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK1562902A V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Indonesia, Month 6 | 1.0 Fold Increase |
| GSK1562902A V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Indonesia, Month 12 | 2.9 Fold Increase |
| GSK1562902A V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Vietnam, Month 6 | 1.7 Fold Increase |
| GSK1562902A V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Vietnam, Month 18 | 2.1 Fold Increase |
| GSK1562902A V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Vietnam, Month 12 | 9.6 Fold Increase |
| GSK1562902A V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Indonesia, Month 18 | 5.7 Fold Increase |
| GSK1562902A V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Indonesia, Month 6 + 7 Days | 25.8 Fold Increase |
| GSK1562902A V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Vietnam, Month 6 + 7 Days | 17.5 Fold Increase |
| GSK1562902A V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Vietnam, Day 21 | 3.0 Fold Increase |
| GSK1562902A V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Indonesia, Day 21 | 1.1 Fold Increase |
| GSK1562902A V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Indonesia, Month 6 + 21 Days | 52.5 Fold Increase |
| GSK1562902A V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Vietnam, Month 6 + 21 Days | 34.7 Fold Increase |
| GSK1562902A V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Indonesia, Month 6 + 7 Days | 12.2 Fold Increase |
| GSK1562902A V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Vietnam, Day 21 | 4.0 Fold Increase |
| GSK1562902A V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Vietnam, Month 6 + 7 Days | 21.6 Fold Increase |
| GSK1562902A V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Vietnam, Month 6 | 2.4 Fold Increase |
| GSK1562902A V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Indonesia, Month 6 + 21 Days | 18.5 Fold Increase |
| GSK1562902A V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Indonesia, Month 6 | 1.1 Fold Increase |
| GSK1562902A V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Indonesia, Month 18 | 3.7 Fold Increase |
| GSK1562902A V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Vietnam, Month 12 | 14.3 Fold Increase |
| GSK1562902A V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Indonesia, Month 12 | 8.9 Fold Increase |
| GSK1562902A V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Vietnam, Month 18 | 2.7 Fold Increase |
| GSK1562902A V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Vietnam, Month 6 + 21 Days | 32.3 Fold Increase |
| GSK1562902A V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Indonesia, Day 21 | 1.3 Fold Increase |
| GSK1562902A 2V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Indonesia, Month 6 + 7 Days | 14.9 Fold Increase |
| GSK1562902A 2V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Indonesia, Month 6 | 1.6 Fold Increase |
| GSK1562902A 2V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Indonesia, Month 6 + 21 Days | 45.3 Fold Increase |
| GSK1562902A 2V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Indonesia, Month 12 | 5.5 Fold Increase |
| GSK1562902A 2V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Indonesia, Month 18 | 6.0 Fold Increase |
| GSK1562902A 2V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Indonesia, Day 21 | 1.1 Fold Increase |
| GSK1562902A 2V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Indonesia, Day 42 | 4.1 Fold Increase |
| GSK1562902A 2V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Vietnam, Day 21 | 5.7 Fold Increase |
| GSK1562902A 2V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Vietnam, Day 42 | 50.3 Fold Increase |
| GSK1562902A 2V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Vietnam, Month 6 | 6.4 Fold Increase |
| GSK1562902A 2V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Vietnam, Month 6 + 7 Days | 6.5 Fold Increase |
| GSK1562902A 2V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Vietnam, Month 6 + 21 Days | 18.3 Fold Increase |
| GSK1562902A 2V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Vietnam, Month 12 | 19.0 Fold Increase |
| GSK1562902A 2V/I/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Vietnam, Month 18 | 1.5 Fold Increase |
| GSK1562902A 2V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Indonesia, Month 6 + 7 Days | 8.6 Fold Increase |
| GSK1562902A 2V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Vietnam, Month 6 + 7 Days | 6.6 Fold Increase |
| GSK1562902A 2V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Indonesia, Day 21 | 1.2 Fold Increase |
| GSK1562902A 2V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Indonesia, Month 18 | 4.3 Fold Increase |
| GSK1562902A 2V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Indonesia, Month 6 | 1.6 Fold Increase |
| GSK1562902A 2V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Vietnam, Month 6 + 21 Days | 11.0 Fold Increase |
| GSK1562902A 2V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Indonesia, Month 12 | 11.6 Fold Increase |
| GSK1562902A 2V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Indonesia, Month 6 + 21 Days | 17.5 Fold Increase |
| GSK1562902A 2V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Vietnam, Month 18 | 1.5 Fold Increase |
| GSK1562902A 2V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Vietnam, Day 42 | 40.8 Fold Increase |
| GSK1562902A 2V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Vietnam, Month 12 | 22.5 Fold Increase |
| GSK1562902A 2V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Vietnam, Month 6 | 6.0 Fold Increase |
| GSK1562902A 2V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Vietnam, Day 21 | 5.4 Fold Increase |
| GSK1562902A 2V/V/6 Group | Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 | A/Indonesia, Day 42 | 4.6 Fold Increase |